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This research portfolio has two chapters. The first chapter is a review of existing research 
and the second is a research study. People who live with an incurable illness may be more 
vulnerable to other health problems, feeling low in mood, and they may face social difficulties. 
Learning skills to manage health problems is called ‘self-management.’ The review of existing 
literature suggests that helping people to learn skills to manage their health problems, through 
‘self-management interventions,’ has a positive effect on their confidence and ability to take 
control of their health problems. This is important because people who can take control of 
their own health often have a better quality of life. More research is needed to find out which 
types of self-management interventions might be most helpful for improving people’s 
confidence in taking control of their own health.  
 
The research study recruited 118 people living with Multiple Sclerosis (MS) to answer written 
questionnaires. The results of the study revealed that when people are aware of and act on 
their own personal values – that is, what is important to them - they might feel more 
confident about managing their health problems. Similarly, people who feel confident about 
the ways they manage their health might be more able to identify their personal values. It was 
also found that people with MS who feel confident and capable of managing their health 
problems are likely to do more to self-manage their condition (e.g. finding out information 
about MS, taking medication regularly and taking a break when tired). Our results also suggest 
that patients, who experience more empathy from their MS specialist nurse or doctor, might 
do more to self-manage their condition; however, it is also possible that when patients 
effectively self-manage, it improves the relationship they have with their clinician. Helping 
people with MS to recognise what is important in their life, and to take positive actions 
towards their values, may allow them to feel more confident in managing their condition. 
Additionally, interventions that aim to build self-management confidence and promote better 
patient-clinician relationships may help some patients to develop the ability to manage their 
MS successfully.
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Full Thesis Abstract 
Purpose: The systematic review explored whether self-management interventions improve 
patient activation in long-term conditions, and if any improvements are greater than the 
amount of change experienced by patients in usual care or active control conditions. It also 
aimed to determine if positive effects on activation are maintained at follow-up. The empirical 
study sought to explore relationships between patient activation, psychological factors 
(depression and valued living), perceived clinician empathy, perceived symptom severity, self-
management and demographic variables. It also examined whether depression, valued living 
and perceived clinician empathy are unique predictors of activation, and if activation is a 
unique predictor of self-management for MS, when relevant confounding variables are 
controlled for.  
  
Methods: For the systematic review, a comprehensive search of multiple electronic 
databases was conducted to identify intervention research reporting on patient activation 
outcomes, as measured by the short-form Patient Activation Measure (PAM-13), in people 
with long-term conditions. For the empirical study, a cross-sectional survey of 118 people 
with MS explored patient activation, MS symptom severity, valued living, depression, 
perceived clinician empathy, self-management for MS and demographic factors. Correlation 
and hierarchical regression analyses were employed to explore relationships between 
variables.  
 
Results: Twenty-five studies were eligible for inclusion in the systematic review, reporting a 
wide range of long-term conditions. Twenty-one studies (10 RCTs; 1 non-randomised study; 
and 10 uncontrolled studies) found an improvement in patient activation at post-intervention. 
Nine studies reported a significantly greater improvement in activation in self-management 
conditions compared with usual care or an active control at post-intervention. In six out of 
eight studies, gains in patient activation were maintained in the intervention group at follow-
up. However, in four of these six studies, patient activation in the control group also 
improved over time. Findings from the empirical study suggested that only valued living was 
a significant predictor of patient activation after controlling for demographic variables and MS 
symptom severity. Neither depression nor perceived clinician empathy significantly predicted 
activation. After controlling for valued living, depression and perceived clinician empathy, 
patient activation independently predicted 5.5% of variance in self-management for MS. Both 
activation and perceived clinician empathy were significant predictors of self-management for 
MS. 
Page 8 of 147 
 
 
Conclusions: Self-management interventions improve patient activation in long-term 
conditions compared with usual care or active control. Patient activation gains appear to be 
maintained longer-term; however, the impact of self-management interventions on activation 
is unclear due to increases in activation in control groups over time. Valued living is associated 
with patient activation in MS, while patient activation and perceived clinician empathy are 
associated with MS self-management. Self-management interventions targeting valued living 
and the patient-clinician relationship may be effective for addressing low levels of activation 
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Purpose: To systematically review the evidence of the effectiveness of self-management 
interventions for improving patient activation, as measured by the short-form Patient 
Activation Measure (PAM-13); to determine if any improvements are greater than the amount 
of change experienced by patients in usual care or active control conditions; and to ascertain 
if patient activation gains are maintained at follow-up of 3 months or beyond. 
 
Methods: A comprehensive search of multiple electronic databases was conducted between 
April and August 2017 (updated in December 2017) to identify intervention research 
reporting on patient activation outcomes, as measured by the PAM-13, in people with long-
term conditions. Uncontrolled studies, together with randomised and non-randomised 
controlled trials, were included and evaluated against quality criteria developed for the 
specific purpose of the review. Authors of included studies were contacted in January 2018 
to identify further published or unpublished literature.  
 
Results: Twenty-five studies were eligible for inclusion in the systematic review, reporting 
on a wide range of physical conditions. Twenty-one studies (10 RCTs; 1 non-randomised 
study; and 10 uncontrolled studies) found an improvement in patient activation in self-
management conditions at post-intervention. Nine studies reported a significantly greater 
improvement in patient activation in self-management conditions compared with usual care 
or active control groups at post-intervention. In six out of eight studies, gains in patient 
activation were maintained in the intervention group at follow-up. However, in four of these 
six studies, improved activation was also found in control groups at follow-up.  
 
Conclusions: Compared with usual care or active control groups, self-management 
interventions improve patient activation in long-term conditions. Patient activation gains 
appear to be maintained longer-term in self-management conditions; however, the impact of 
self-management interventions on activation is unclear due to increases in activation in 









The effort to promote and prolong quality of life in long-term conditions (LTCs) within the 
context of increasing global life expectancy creates challenges for healthcare systems 
worldwide (Wang et al., 2016). According to the UK Global Burden of Disease Study (2010), 
the number of years lived with a disability is on the rise because of the increased prevalence 
of many chronic conditions with age (Murray et al., 2013). LTCs are defined as those that are 
not curable at present but may be managed, to some extent, by medication or other therapies 
(Department of Health [DoH], 2012). In England, approximately 15 million people live with 
a LTC, with care costs accounting for around 70% of the English health and social care budget 
(DoH, 2012). In Scotland, around 2 million people live with at least one LTC (The Scottish 
Government, 2009). The management of LTCs is typically dependent on the unique features 
of the specific condition; however, due to increased demand upon health care services, 
patient ‘self-management’ has gained increased prominence and is typically seen as a core 
component of contemporary models of care (Taylor et al., 2014).  
 
What is self-management? 
 
Barlow, Wright, Sheasby, Turner and Hainsworth (2002, p. 178) define self-management as 
“the individual’s ability to manage the symptoms, treatment, physical and psychosocial 
consequences and lifestyle changes inherent in living with a chronic condition.” Self-
management discourse is embedded in health guidelines, whereby the patient is encouraged 
to adopt an empowered, active role. The task of the healthcare professional is to share power 
and responsibility in the effort to promote patient autonomy, participation and decision-
making in healthcare (Ellis et al., 2017). As a result, it is perhaps unsurprising that self-
management is typically viewed in behavioural terms, where the DoH (2007) defines self-
management of LTCs as the actions taken by individuals to support their own health and 
wellbeing. However, according to Barlow et al. (2002), effective self-management is 
dependent upon an individual’s ability to self-monitor and flexibly bring about the cognitive, 
emotional and behavioural adjustments in order to preserve quality of life for as long as 
possible. It is widely accepted that self-management is more than adhering to treatment 
guidelines; it must also incorporate the psychological and social management of living with a 
chronic condition. The extent of psychological and social management required is dependent 
on the LTC, and subsequently what is necessary for effective self-management (Newman, 
Steed & Mulligan, 2004). For example, self-management of asthma might only entail using an 
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inhaler when required to prevent symptom exacerbations; whereas self-management for 
progressive MS may need medication adherence in the form of injections, behavioural changes, 
social and psychological coping strategies because of the extent and impact of symptoms on 
several areas of life. 
 
Taylor et al. (2014) define a self-management intervention (SMI) as those that provide patients 
with education, training and support to develop knowledge, skills or psychological and social 
resources to undertake activities to manage a health condition. Taylor et al.’s (2014) 
proposed taxonomy of self-management components, to capture the range of self-
management programmes offered across setting, disciplines, and diseases, comprises: 
 
• Information provision;  
• Psychological coping skills to help with adjustment;  
• Specific action plans to support adherence to treatments;  
• Practical assistance that is condition-specific (e.g. activities of daily living or training 
to enable self-management of specific tasks);  
• Regular social or clinical support;  
• Communication training; 
• Guidance or advice on lifestyle alterations. 
 
As well as differing on the basis of underlying health conditions, some studies have found that 
levels of engagement in self-management may vary in relation to age and gender (Blakemore 
et al., 2016; Bos-Touwen et al., 2015) and have a significant impact on the types of behaviour 
individuals engage with regarding their condition. For example, a man in his 70s with 
cardiovascular disease may take on a passive mentality of “do whatever the doctor decides 
to do.” By contrast, a woman in her 40s with diabetes may wish to find out information about 
coping with diabetes via the internet and discussions with the diabetes nurse; she may also 
alter aspects of her lifestyle (e.g. making time for physical activity, paying attention to dietary 
sugar and wearing a pedometer to self-monitor) according to this advice. The aforementioned 
examples highlight the variability among individuals with LTCs concerning self-governance, 
monitoring and personal responsibility. It can be argued, therefore, that a patient’s ability to 
engage in self-management behaviours is dependent on their knowledge, skill and confidence 
for managing their own health and healthcare, typically conceptualised as ‘patient activation’ 
(Hibbard, Stockard, Mahoney & Tusler, 2004). 





The patient activation construct has emerged on a background of policy directions that aim 
to empower patients and improve the quality of care in LTCs (Wagner et al., 2001). The 
Chronic Care Model (see Wagner et al., 2001) is a framework that encapsulates the systemic 
components required to improve care in LTCs including patients, carers and healthcare teams. 
The model suggests that improving care requires interventions at each of the systemic levels, 
with interactions between informed patients and healthcare professionals as a key component 
leading to improved management of LTCs (Bodenheimer, Wagner & Grumbach, 2002). 
However, as highlighted by Hibbard, Mahoney, Stockard and Tusler (2007), the patient 
activation construct has historically been an underdeveloped aspect of the Chronic Illness 
Care Model, both in conceptual and empirical terms. The patient activation construct 
assimilates the closely related psychological constructs of self-efficacy (Lorig et al., 1996), 
locus of control (Wallston & Wallston, 1982) and readiness to change (Prochaska & 
DiClemente, 1986), but also comprises aspects of personal capability including 
communication skills, disease knowledge and attitudes regarding self-agency (Skolasky, 
MacKenzie, Riley & Wegener, 2009). While existing constructs traditionally assess specific 
psychological variables or behavioural outcomes; the development of the patient activation 
construct, and its measurement, sought to bring together both psychological and behaviour 
components thought to be involved in activation which can be applied transdiagnostically 
across illness groups for clinical and research purposes (Hibbard et al., 2004).   
 
The patient activation construct captures beliefs and attitudes about acquiring and building 
skills, in addition to the actual implementation of self-management activities (Moore et al., 
2016). It is a progressive process, whereby an individual who is more “activated” will 
demonstrate greater endorsement of the behaviours, attitudes and beliefs needed for illness 
self-management (Hibbard, Mahoney, Stockard & Tusler, 2005). The short-form Patient 
Activation Measure (PAM-13), the most widely used measure of this construct, is a 13-item 
self-report scale assessing skills, knowledge and confidence in illness self-management. 
Responses to items such as “I am confident that I can follow through on medical treatments I need 
to do at home” are rated from ‘strongly disagree’ to ‘strongly agree.’ Responses are converted 
to a 0-100 scale; with higher scores indicating greater levels of patient activation. The PAM-
13 has demonstrated utility by linking activation levels to health outcomes, costs, and patients’ 
experiences of care (Bodenheimer, Lorig, Holman, & Grumbach, 2002). According to the 
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authors of PAM-13 (Hibbard et al., 2005), there are four developmental increments in 
becoming a ‘competent self-manager.’ As individuals move through each stage, it is suggested 
that their autonomy and competence in self-management improves. The activation levels and 
basic descriptors are (Dixon, Hibbard & Tusler, 2009; Hibbard & Gilburt, 2014; Hibbard et 
al., 2007): 
 
• Level 1: individuals play a passive role in their own health and are not actively involved in 
their healthcare provision. They may lack understanding of their role in their own 
healthcare and view self-management in terms of simple compliance.  
o Example: The person who “just follows the doctor’s orders,” such as taking medication 
when they feel no benefit or have no knowledge of what their medication does. They 
may be forgetful and inconsistent in adherence. 
 
• Level 2: individuals may have a basic understanding of their health and healthcare needs 
but lack skills and / or confidence to manage their health effectively.  
o Example: The person, who is increasingly aware of the importance of finding out about 
their condition and talks with others about their condition, but who may not be confident 
or skilled in carrying out actions to support their health (e.g. doing exercise inconsistently 
to manage weight). 
 
• Level 3:  individuals have most of the facts about their health condition and are starting 
to take specific actions pertaining to managing their condition but may still lack some 
confidence and skills in managing their health. 
o Example: The person who views their relationship with their healthcare provider as 
primarily a partnership, engages in multiple health-supporting behaviours to manage 
their health (e.g. lifestyle changes, taking medication), though may struggle in areas of 
self-monitoring and managing multiple behavioural changes to some degree. 
 
• Level 4: individuals are carrying out behaviours necessary to support their health and 
manage their condition; however, maintenance of these behaviours may be difficult in the 
face of life stressors. Individuals will view self-management in terms of being in control 
and responsive to changes when needed. 
o Example: The person, who is engaging in various health-supporting behaviours to 
manage their own healthcare, recognises the impact of stress on their self-management 
and can effectively manage this impact via self-monitoring most of the time.  
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Patient activation and positive health outcomes 
 
There is evidence that individuals scoring highly on the PAM-13 are more likely to engage in 
health-supporting behaviours such as eating healthily and exercising regularly (Forbat, Cayless, 
Knighting, Cornwell & Kearney, 2009; Hibbard et al., 2007). Furthermore, individuals who 
score highly are significantly more likely to avoid health-limiting behaviours such as smoking 
and substance misuse (Greene & Hibbard, 2012). 
 
Patients with LTCs who are more activated have also been found to be significantly more 
likely to adhere to treatment recommendations and self-monitor at home, prepare questions 
in advance of a medical appointment and seek information regarding their condition (Fowles, 
Terry, Hibbard, Bloom & Harvey, 2009; Hibbard, Greene & Tusler, 2009; Mosen et al., 2007). 
Moreover, the link between patient activation and health outcomes appears to be consistent 
across various health conditions, continents and diverse demographic backgrounds (Greene 
& Hibbard, 2012).  
 
Several studies have shown that increases in patient activation positively correlate with health 
behaviours including the uptake of regular exercise, adherence with medication (Hibbard et 
al., 2007; Mosen et al., 2007), information seeking (Fowles et al., 2009), glucose testing, foot 
checks and eye examinations in diabetic patients (Rask et al., 2009; Remmers et al., 2009). 
Furthermore, low levels of self-reported activation have been found to predict hospital 
readmission within 30 days in patients with a range of physical health problems (Mitchell et 
al., 2014). These findings appear to suggest that the PAM-13 has predictive value in 
determining those likely to engage in self-management behaviours and, arguably, might be 
viewed as a transdiagnostic measure through which patient engagement in self-management 
can be captured. 
 
Why examine patient activation as an outcome? 
 
Patient activation is thought to be a modifiable construct (Hibbard et al., 2007) as evidenced 
by its increasing prominence as an outcome in a range of clinically important health indicators 
in studies evaluating the effectiveness of SMIs. Across many chronic conditions including heart 
failure, type II diabetes, and polyarthritis (Grønning, Skomsvoll, Rannestad & Steinsbekk, 2012; 
Lorig, Ritter, Villa & Armas, 2009; Shively et al., 2013) SMIs have been found to increase 
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patient activation, although these findings are not consistent across studies (Rygg, Rise, 
Grønning, & Steinsbekk., 2012; Ryvicker, Feldman, Chiu, & Gerber, 2013).  
 
SMIs claim to ‘activate’ patients and improve engagement with self-management; however, 
Moore et al. (2016) suggest that the range and quality of outcome measures used to evaluate 
SMIs are highly variable. Some studies use disease-specific self-efficacy measures, others rely 
on patient self-report of specific behaviours, while others use quality of life measures. 
Furthermore, the variation between the quality and content of SMIs adds an additional 
complexity in making sense of this literature. Moore et al. (2016) recommended that, among 
others, data on patient activation should be gathered in evaluations of SMIs as measures such 
as the PAM-13 capture information on the array of knowledge, skills and beliefs a person 
needs to effectively self-manage their LTC.  
 
In a review of the literature, Bolen et al. (2014) sought to evaluate the effectiveness of a range 
of patient activating interventions for adults with diabetes on several clinical outcomes 
including diabetes control. The results demonstrated these interventions safely and modestly 
improve diabetes control; however, an important methodological limitation of this review 
was that the authors did not examine the effectiveness of these interventions in improving 
patient activation as a possible mediator or moderator of change.  
 
There is a need to review the current health literature in disease management to evaluate 
the effectiveness of SMIs for improving patient activation. While SMIs are heterogeneous in 
nature, reviewing the evidence for patient activation outcomes in this area has the potential 
to add to our understanding of the effectiveness of self-management interventions in line with 




We aimed to evaluate the available evidence regarding the effectiveness of SMIs in improving 
patient activation, as measured by the PAM-13, in adults with chronic physical health 
conditions. A secondary aim was to evaluate if any positive impact of SMIs on patient 
activation are maintained at 3 months follow-up or beyond.




2.1 Protocol  
 
This review was registered on PROSPERO: 
https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=72292, registration 
number CRD42017072292. Amendments to the protocol during the review are also 
available on this record. 
 
2.2 Selection of studies for inclusion 
 
Development of the study protocol and reporting was informed by the Centre for Reviews 
and Dissemination (CRD; 2009) and the PRIMSA recommendations (Moher, Liberati, Tetzlaff 
& Altman, 2009). The ‘PICOS’ method comprising: population, intervention, comparators, 
outcomes and study design, guided the eligibility criteria for studies as shown in Table 1.
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Table 1. PICOS eligibility criteria for selection of studies. 
 Inclusion criteria Exclusion criteria 
Population 
 
• Adults (≥16 years) living with a 
specified long-term physical health 
condition(s), in clinical and non-
clinical settings. Studies may 
include individuals with mental 
health problems where physical 
health problems were documented 
in at least 70% of the total 
sample. 
• Children and adolescents (<16 years), or 
adults without a long-term condition(s). 
Interventions 
 
• Self-management interventions 
delivered in any context or setting 
to increase patient activation as a 
primary or secondary outcome. 
• Interventions considered insufficient for 




• No specifications set for 
comparative conditions (e.g., usual 
care, wait-list, active control). 




• Patient activation as measured by 
the short-form Patient Activation 
Measure (PAM-13); 
• Pre- and post-intervention or pre-
intervention and follow-up data for 
PAM-13. 





• Randomised controlled trials; non-
randomised trials and 
observational repeated-measures 
designs, including case series, 
conducted from January 2004 to 
present; 
• Published or unpublished research 
in any language. 
• Small N designs  
• Studies with very underpowered 
intervention groups (n <9) due to their 
inability to appropriately address the 
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2.3 Search strategy for identification of studies 
 
Electronic database searches  
  
The search strategy was developed in consultation with a senior university librarian 
experienced in systematic literature reviews. Initial searches were conducted between April 
and August 2017 and updated in December 2017. An initial search of Database of Abstracts 
of Reviews of Effects (DARE), Cochrane Database of Systematic Reviews (CDSR) and 
PROSPERO was carried out to investigate the scope of other reviews in this area and to 
ensure the research question had not previously been addressed. 
 
The OVID gateway was used to search the following databases: EMBASE (1980 to August 
2017), PsycINFO (1806 to August 2017), and OVID MEDLINE(R) (1946 to August 2017). 
EBSCO host was used to search CINAHL Plus and ProQuest was used to search Applied 
Social Sciences Index and Abstracts (ASSIA) (1987 to present). The following search terms 
were used: “patient activation” AND “self management” OR “self manag*” OR “self care” 
AND “chronic” OR “long term.” 
 
ProQuest Dissertations & Theses Global and the Electronic Theses Online Service (EThOS), 





Further to the database search strategy, manual searches were also conducted to capture 
potential additional papers in the literature missed by the search terms. All papers referenced 
in the originally identified studies and relevant reviews retrieved through database searches 
were examined. A Google Scholar search using the aforementioned search terms was 
performed, with the first ten pages reviewed for additional articles. Publications, which cited 
the included studies were also screened using Google Scholar. Finally, authors of eligible 
studies were contacted to identify any further studies which may have been missed or in 
progress. 
Page 20 of 147 
 
2.4 Data collection and analysis 
 
Selection of studies 
 
The first author determined study eligibility for inclusion. Titles and abstracts of retrieved 
studies were reviewed in the initial stage of screening. Studies were retained for the inclusion 
at this stage if the title and/or abstract suggested that the study evaluated a self-management 
intervention. The full text of articles retained following title/abstract screening were 
subsequently reviewed against inclusion criteria. See Figure 1 for an overview of the search 
strategy and review stages.  
 








N = 475 
Excluded on 
abstract basis 
N = 433 
Studies identified 
for title review 
N = 1, 226 
Excluded on 
title basis 
N = 751 
Studies identified by database search 
strategy 
(PsychINFO; Embase; Medline; Cochrane; 
CINAHL, ASSIA; ProQuest; ETHOS) 
N = 1,568 
Duplicates 
removed 




N = 42 
Excluded on full paper review basis: 
Conference abstract when full text 
not available (n = 7); 
Wrong intervention (n = 4) 
Wrong population (n = 4) 
Wrong outcome measure (n = 2) 
Insufficient sample (n = 1) 
Wrong design (n = 1) 
Total N = 19 
 
Studies identified by manual search 
strategy  
(References; Google Scholar; Contact with 




N = 24 
Identified from 
reference sections & 
relevant reviews  








N = 15 
Excluded on abstract 
basis 
N = 72 
Excluded on full paper 
review basis: 
Wrong outcome 
measure (n = 8) 
Wrong design (n = 5) 




N = 2 
Studies 
included  
N = 23 
Total papers included  
N = 25 
Identified via author 
contact  
N = 9 
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Data extraction and management 
  
The first author, using a data extraction form employed in a previous study by Chauhan, 
Morris and Ferreira (2016), performed data extraction for the current review. The data 
extraction form included the following information: author and publication date; study design; 
brief description of the intervention and control (if any); mean age; gender; sample; duration 
of the intervention and follow-up period.  
 
For this review a coding frame based on the taxonomy developed by Taylor et al. (2014) was 
used to identify the components of each intervention to allow for decision-making around 
the complexity and suitability of the self-management approaches in the reviewed papers (see 
Appendix B). Each intervention was reviewed for its suitability for improving patient 
activation. The first author coded each intervention according to this coding frame and a 
second coder following detailed instructions validated the results. Any disagreements were 
resolved by discussion. 
  
Assessment of methodological quality of included studies  
 
In their current form, typical risk of bias tools or quality criteria were not felt to be 
appropriate for our research question. This issue was further compounded by the 
idiosyncratic nature of self-management interventions and the variation in methodological 
design of the included studies (e.g. RCTs and repeated-measures designs). Therefore, a set 
of quality criteria with the ability to assess studies for the current review were adapted from 
existing tools. The criteria developed for the purposes of this review can be viewed in Table 
2 (see Appendix C for an operationalisation of the criteria).  
 
All studies were assessed for quality by the first author and a second rater using the same 
quality criteria tool blindly assessed a randomly allocated proportion of studies (50%). The 
quality ratings were then crosschecked, and any discrepancies were resolved through 
discussion. Interrater reliability ranged between 0.85 and 1.00 across items. 
 
The methodology checklist (Scottish Intercollegiate Guidelines Network [SIGN], 2012) was 
considered in relation to each criterion and the following ratings were employed: well 
covered (3 points), adequately addressed (2), poorly addressed (1), and not reported / not 
addressed (0). The highest overall score a study could receive was 39. A previous review 
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conducted by Pateraki and Morris (2017) utilised the quality classification system of ++, + or 
– based on guidelines by SIGN (2012). Studies were coded ‘++’ where the overall rating was 
≥75% (30-39); coded ‘+’ where overall rating was ≥50% (20-29); and coded ‘-’ where overall 




Table 2. Quality criteria for included studies. 
 
Risk of bias quality criteria 
1. Design:  
Study design provides sufficient evidence that patient activation outcome is due to the intervention 
2. Recruitment: 
Recruitment method and eligibility criteria were appropriate to ensure a representative and suitable 
sample 
3. Sample size:  
Sample size (power) is sufficient for analysis relating to pre-and post- patient activation outcome 
4. Allocation bias:  
Allocation process was appropriate to address allocation bias 
5. Equal groups:  
Groups are comparable at baseline on key variables (i.e., patient activation, severity of condition, age, 
gender, education, where appropriate) 
6. Measure validity:  
PAM-13 was appropriately administered and validated for use in sample population 
7. Follow-up:  
Follow-up measure was administered to evaluate if effects are maintained long-term 
8. Intervention suitability:  
Self-management intervention is suitable for increasing patient activation outcome 
9. Intervention delivery & assessment:  
Delivery of the intervention was conducted and assessed appropriately 
10. Attrition (1): 
Post-intervention attrition was low and/or comparable to control group 
11. Attrition (2):  
Follow-up attrition was low and/or comparable to control group 
12. Analysis:  
Analysis is appropriate for the review aims, measure or design and outcomes are appropriately 
reported 
13. Missing data:  
















Figure 1 illustrates that 1,568 papers were initially identify through electronic database 
searches. The number of papers retained for review following each stage of the screening 
process and rationales for exclusion are detailed thereafter. Manual searches of the literature 
resulted in two further papers being identified as eligible for review.  
 
3.1 Summary characteristics of included studies 
 
In total, 25 studies satisfied inclusion criteria for review. Summary characteristics of included 
studies are detailed in Table 3. Of the 25 studies that met inclusion criteria, 13 studies were 
randomised controlled trials (RCTs). Of these, nine RCTs compared an SMI with usual care 
control; two RCTs compared an SMI with an alternative active control; and a further two 
RCTs compared an SMI with both treatment as usual and an active control. There were two 
non-randomised controlled studies, in which the control groups used were usual care and an 
alternative active control. The remaining 10 studies were uncontrolled repeated measures 
designs. 
 
The SMIs were delivered in a variety of formats but could be classified as group/workshop 
interventions (11 studies), individual interventions (10 studies) and web-based interventions 
(four studies). The mean percentage of females in the intervention condition across studies 
was 57.22%, with a range of 0-100 percent. The duration of SMIs differed between formats; 
group and web-based SMIs typically lasted for six weeks (range: six to twelve weeks) 
compared with one-to-one SMIs which lasted approximately six months (range: one to twelve 
months). One-to-one SMIs appeared to offer the greatest intensity among the three 
intervention formats. Eight studies included follow-up periods of either three months (one 
study), six months (two studies), twelve months (four studies) or eighteen months (one 
study).  All studies used the short-form Patient Activation Measure (PAM-13; Hibbard et al., 
2005). 
 
A summary of the methodological quality criteria ratings is provided in Figure 2.  Areas of 
relative methodological strength across the literature were in the domains of measure validity 
within sample populations, intervention suitability and sample size. Areas of methodological 
weakness across studies were use of follow-up measures, attrition rates at follow-up and 
allocation bias.  
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3.2 Risk of bias and quality assessment 
 
Risk of Bias and Quality Assessment ratings for each reviewed study are outlined in Table 4 
and summarised in Figure 2. An independent co-rater also examined fourteen of the papers. 
Studies to be co-rated were selected via a randomly generated series of numbers by 
random.org. Agreement was reached on 156/182 ratings (i.e. 85.7%). In six ratings, 
disagreement of more than one point was found. These discrepancies were discussed, and 
agreement was reached by consensus. The criteria were then amended to improve clarity 




Of the 13 RCTs, seven obtained the highest ratings (++) (Ehde et al., 2015; Grønning et al., 
2012; Hibbard et al., 2007; Lorig et al., 2009; Lorig et al., 2010; Rygg et al., 2012; Shively et al., 
2013). The remaining RCTs and both non-randomised trials were allocated an overall rating 
of (+) (Hibbard et al., 2009; Hochhalter, Song, Rush, Sklar, & Stevens, 2010; Maindal, Sandbæk, 
Kirkevold, & Lauritzen, 2011; Morrison et al., 2016; Ryvicker et al., 2013; Solomon, Wagner, 
& Goes, 2012; Titova et al., 2017; Young, Hertzog & Barnason, 2016). Of the 10 uncontrolled 
studies, seven were given a rating of (+) (Fløde, Iversen, Aarflot & Haltbakk, 2017; Kaltman 
et al., 2015; Kawi, Schuerman, Alpert, & Young, 2015; Kosmala-Anderson, Wallace, Turner 
& Bourne, 2014; Shah et al., 2015; Turner, Anderson, Wallace, & Kennedy-Williams, 2014; 
Turner, Anderson, Wallace, & Bourne, 2015). Three were allocated the poorest rating (-) 
(Crosby, Joffe, Peugh, Ware & Britto, 2017; Ledford, Ledford, & Childress, 2013; Wallace et 
al., 2009). 
 
Power and sample representativeness 
 
Sample sizes were generally adequate and in intervention conditions ranged from 16 to 1170 
participants (4,280 intervention participants across 25 studies; M=171.2, SD=229.35). Good–
to-moderate attrition rates for intervention conditions were found across studies, ranging 
between 0%-50 percent. The majority of studies utilised suitable analyses (n = 23) and 
addressed missing data appropriately (n = 18) to examine the effect of the intervention on 
patient activation. Post-hoc power analyses for pre-post results in each study’s intervention 
groups were conducted. Using the G*power programme, a medium effect size was 
anticipated (d = 0.5 for t-test; f = 0.25 for ANOVA) and α = 0.05. By this method, 19 of the 
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25 studies had a sample size sufficient to achieve power of ≥0.8. The remaining six studies 
had samples sufficient to achieve power of ≥0.6 to <.80. 
 
Recruitment methods were generally adequate. Convenience sampling was evident 
throughout studies, though most specified eligibility criteria (e.g. physician confirmed 
diagnosis, presence of comorbidity or depression) which would allow for results that were 
reasonably representative and generalisable within the specified illness groups. Five studies 
had samples comprising clearly identified heterogeneous health conditions (Hibbard et al., 
2007; Hibbard et al., 2009; Hochhalter et al., 2010; Solomon et al., 2010; Turner et al., 2015). 
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Table 3. Characteristics of included studies. 
 
 





Patient Group Duration Follow-
up 
2017 Crosby et al. Uncontrolled 
study 
Chronic Disease Self-Management 
Program  
18.7 (2.22) 22 (45.5) Young adults with sickle 
cell disease 
6 weekly 2.5 hr 
sessions 
6 months 




54 (12) 115 (47) Adults with type II 
diabetes 
12-15 hrs over 2/3 
weeks 
3 months 
2017 Titova et al. Non-
randomised 
Home-based self-management 
programme integrating disease 
education, e-learning, skill building 












Adults with COPD 6 months None 
2016 Morrison et 
al. 














2016 Young et al. RCT Self-management training in 
hospital & telephone 










Adults with heart failure 1 x 1-1 training + 




2015 Ehde et al. RCT Telephone-delivered self-
management intervention 

















Behavioural activation and 
motivational interviewing sessions 
49.7 (8.8) 18 (56) Adults with type II 
diabetes and depression 




2015 Kawi et al. Uncontrolled 
study 
Online self-management program 
combined & physical activity 
60.9 16 (100) Adult females (50+) 
with knee osteoarthritis 
6 weekly 2hr online 
self-management 
modules + 3x weekly 
exercise sessions for 
10 weeks. 
None 
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Patient Group Duration Follow-
up 
2015 Shah et al. Uncontrolled 
study 
Disease-specific educational classes 
+ peer support groups + home-
based monitoring + individualised 
exercise and nutritional goals 
49.4 (12) 60 (68) Adults with type II 
diabetes 
1hr didactic group 
session + monthly 
home-based 
educational sessions 
for 6 months 
None 
2015 Turner et al. Uncontrolled 
study 
Disease self-management program 56.3 (14.6) 1170 (64) Adults with mixed long-
term conditions 
(diabetes, depression, 
skeletal pain, COPD) 
7 weekly 3hr sessions None 
2014 Turner et al.  Uncontrolled 
study 
Chronic Disease Self-Management 
Program tailored for COPD 








62.3 (11.1) 285 (51.3) Adults with type II 
diabetes 
7 weekly 3hr sessions None 
2013 Ledford et al. Uncontrolled 
study 
Patient-physician communication 
coaching and education 
59.8 (8.9) 128 (48.4) Adults with type II 
diabetes 
Brief 1-1 clinic 
appointment + 
tailored postcard 
reminder after 2 
weeks + tailored 
letter reminder after 
4 months 
None 
2013 Ryvicker et 
al. 
RCT Home Support Program 
Vs. Evidence-based 
recommendations to nurse and 
patient 












12 months None 









Adults with CHF 6 sessions over 6 
months 
None 
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Patient Group Duration Follow-
up 
2012 Grønning et 
al. 
RCT Disease-specific educational and 
skills-based group plus tailored 
individual education session  









Adults with chronic 
polyarthritis 
3x 3hr group sessions 








66 (overall) 73 (45 
overall) 
73 
Adults with type II 
diabetes 
15hrs over 3 sessions 12 
months 
2012 Solomon et 
al. 
RCT Access to personalised online 
portal with interactive health 
applications and educational 
modules 
Access to non-interactive health 
education website 




Adults with diabetes, 
asthma hypertension or 
‘other’ 
24hr access for 12 
weeks 
None 









Adults with type II 
diabetes and 
dysglycaemia 
2 x 1-1 counselling 
sessions + 8 group 








RCT Skills-based patient-doctor 
communication workshop and 
health coaching 












Older adults with at 
least 2 chronic 
conditions (arthritis, 





















Adults with type II 
diabetes 
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Patient Group Duration Follow-
up 




Tailored telephone coaching 





Adults with a primary 
diagnosis of asthma, 
COPD, CAD, CHF or 
diabetes 
6 months None 







Adults with type II 
diabetes 








Diabetes education and brief 




250 (64.8) Adults with type II 
diabetes 
Initial 1-1 session + 2 
telephone sessions 
over 1 month 
None 
2007 Hibbard et 
al. 









Older adults with at 
least 1 chronic 
condition (diabetes, 
arthritis, hypertension, 
heart disease, COPD, 
hyperlipidaemia) 





Abbreviations: CAD: coronary artery disease; CHF: chronic heart failure; COPD: chronic obstructive pulmonary disease; RCT: randomised controlled trial; TAU: treatment as usual
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* See Table 2 and Appendix C for details of quality criteria 
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Well covered Adequately addressed Poorly addressed Not reported / N/A




Intervention components were identified based on the information available in each study 
and used to inform quality ratings. Nineteen studies appeared to provide a sufficiently detailed 
SMI to increase patient activation in terms of content, duration, intensity and professional 
input. Six studies were allocated a rating of ‘adequate’ for intervention suitability as they may 
have lacked the multiple components considered necessary for increasing activation. For 
example, disease-specific education or skills training/rehearsal of practical self-management 
tasks (see Appendix B) (Fløde et al., 2017; Hibbard et al., 2009; Hochhalter et al., 2013; 
Ledford et al., 2013; Rygg et al., 2012; Solomon et al., 2012). Two of these studies received a 
lower rating as replication would not have been feasible due to wider reporting issues within 
the papers. Three of the included studies provided minimum or no condition-related 
education (Hibbard et al., 2009; Hochhalter et al., 2010; Kawi et al., 2015).  
 
Significant variation was observed in the training of intervention facilitators. This ranged from 
psychologists (e.g. Turner et al., 2015) to nurses, physiotherapists and dieticians (e.g. Maindal 
et al., 2011) to trained community health-workers (e.g. Shah et al., 2015). Intervention 
delivery and fidelity was adequately or well addressed in 18 of the 25 studies. Six studies 
reported no information regarding facilitators and procedure to assess adherence to the 
treatment protocol making replication difficult or impossible (Crosby et al., 2017; Grønning 
et al., 2012; Morrison et al., 2016; Solomon et al., 2012; Titova et al., 2017; Young et al., 2016). 
In the cases of Solomon et al. (2012) and Morrison et al. (2016), this quality criterion was not 
applicable as the interventions were purely web-based with no facilitator input. 
 
Outcome measures and follow-up 
 
Most studies provided either psychometric data for the PAM-13 in the included sample, 
where the alpha level was sufficient to be considered good, or psychometric properties within 
the study population had been provided elsewhere. In one study (Turner et al., 2014), 
psychometric data for the measure was not available for a specific condition (Chronic 
Obstructive Pulmonary Disease) but was rated ‘well covered’ as good psychometric data 
were available in similar populations, where there was good reason to believe they would 
apply to the population present in the study (e.g. lung disease). Only eight studies examined 
intervention effects ≥3 months beyond post-treatment, of which, six were RCTs (Ehde et al., 
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2015; Grønning et al., 2012; Hibbard et al., 2007; Lorig et al., 2009; Lorig et al., 2010; Rygg et 
al., 2012). 
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Significant increase in patient activation from baseline (Mean (SD) 65.7 (10.0)) to 
post-intervention (Mean (SD) 73.0 (13.9), p<.001) within intervention group. 
Significantly higher patient activation in intervention group compared with the 
control group at post-intervention (Estimated mean difference (95% CI) 7.72 
(0.53 to 14.90), p=.036). 
Hedges g =.60* Hedges g =.47* N/A 
Young et al. 
(2016) 
Significant increase in patient activation from baseline (Mean (SD) 57.3 (19.2)) to 
post-intervention (Mean (SD) 69.1 (16.7) p<.001) within intervention group. 
No significant differences between intervention and control group at post-
intervention at .05 significance level (p=.069). 
Hedges g =.65* N/A N/A 
Ehde et al. 
(2015) 
Significant increase in patient activation from baseline to post-intervention within 
intervention group (mean change score (95% CI) 9.1 (-10.3, -5.29) p<.05) and 
control group (mean change score (95% CI) 4.1 (-6.35, -1.98) p<.05). 
Significantly higher patient activation in intervention group compared with 
control group at post-intervention (mean change score (95% CI) 6.9 (-.92, -.23), 
p<.05). 
Hedges g =.81* Hedges g =.58* 
Patient activation score maintained 
within intervention group but 
between-group differences no 




No significant change in patient activation relative to usual care. N/A N/A N/A 
Shively et al. 
(2013) 
Significant increase in patient activation from baseline (Mean (SD) 61.3 (16.61)) to 
post-intervention (Mean (SD) 71.5 (17.43), p<.001) within intervention group. 
Significant increase in patient activation between groups (significant group x time 
interaction, F=3.73, p=.03). 
Significant group x activation level x time interaction (F=3.89, p=.005). 
Intervention group improved more over time compared with usual care with 
effects most clearly and strongly present for those moderately activated at 
baseline. 
Hedges g =.59* ηp2 =.06 N/A 


















Significant increase in patient activation from baseline to post-intervention within 
intervention group (mean change score (95% CI) 3.07, (-6.2, 0.0), p=.05). 
Significantly higher patient activation in intervention group compared with 
control group at post-intervention (mean change score (95% CI) 5.98, (1.8, 10.2), 
p=.01). 
Hedges g =.21* 
 
Hedges g =.37* 
Activation change maintained within 
intervention group after 12 months. 
Between group analyses for 
differences in patient activation 
approached significance at 12-month 
follow-up (mean change score (95% 
CI) 3.9 (-0.3, 8.0), p=.069) 
Rygg et al. 
2012 
No statistically significant differences between intervention and control group 
found. 
Sub analyses found patients with poorest diabetes control in intervention group 
had significantly higher patient activation post-intervention compared with 




Hedges g =.64* 
N/A 
Sub analyses: 
Hedges g =.50* 
No statistically significant differences 





Significant increase in patient activation from pre- to post-intervention within 
intervention group (mean 5.967, SD 9.70, t (57) =4.683, p<.001). 
Significantly higher patient activation in intervention group compared with 
control group at post-intervention (F (1,123) =4.438, p=.04, r=.196). 
Sub analyses found significant difference in mean change over time for low, 
moderate and highest activated patients in intervention group (F (2, 55) =6.472, 
p=.003, r=.436). Post hoc analysis found significantly lower mean change in 
highest activated group, compared with moderately (mean difference (95% CI) –
8.354 (–15.06, –1.64), p=.01, d=.45) and lowest activated group (mean difference 
(95% CI) –8.457 (–15.47, –1.45), p=.01, d=.45). 
Hedges g =.42* Hedges g =.18* N/A 
Maindal et al. 
2011 
Increase in patient activation in intervention group but results not statistically 
significant. 
N/A N/A N/A 
Hochhalter 
et al. (2010) 
Significant increase in patient activation from baseline (Mean (SD) 57.1 (13.2)) to 
post-intervention (Mean (SD) 66.8 (18.5) p<.001) within intervention group. 
Hedges g =.60* N/A N/A 
















No statistically significantly change in patient activation between groups over 
time. 
Lorig et al. 
(2010) 
Significant increase in patient activation from baseline (Mean (SD) 64.9 (14.4)) to 
post-intervention (Mean (SD) 70.6 (14.4) p<.001) within intervention group. 
Significantly higher patient activation in intervention group Mean (SD) 70.6 (14.4)) 
compared with control group at post-intervention (Mean (SD) 68.13 (14.4), 
p=.02). 
Hedges g =.40* Hedges g =.17* 
Intervention group showed 
significantly greater improvements in 
patient activation compared with 
usual care control (p=.016) at 18-
month follow-up but result not 
significant following ITT analysis 
(p=.052). 
 
Lorig et al. 
(2009) 
Significant increase in patient activation from baseline (Mean (SD) 62.9 (17.8)) to 
post-intervention (Mean (SD) 67.4 (15.8), p<.001) within intervention group. 
Significantly higher patient activation in intervention group compared with 
control group at post-intervention (mean (SD) 4.52 (15.8) vs 1.75 (15.3), p=.017) 
Hedges g =.27* Hedges g =.17* 
Intervention participants 
demonstrated continued improved 
patient activation at 12 months 
(mean change (SD) 4.30 (14.4), 
p=.007) compared with baseline but 
no comparison with control group. 
Hibbard et al. 
(2007) 
Significant increase in patient activation for both groups over time (F=45.1, 
p.001).  Significant increase in patient activation scores over time for 
Intervention group compared with control group (F=13.44, p.001). 
Not extractable ηp2 =.03 
Patient activation maintained in 
intervention group at 6-month 
follow-up but between-group 
differences no longer significant due 
to improvement in patient activation 
in control group at 6-month follow-
up (F=2.344, p=.127). 
Titova et al. 
(2017) 
No statistically significant changes in patient activation within or between groups. N/A N/A N/A 
Hibbard et al. 
(2009) 
From pre-to post-intervention, intervention group had 4.6-point gain in 
activation; control group had 2.6-point gain. Intervention group change in patient 
Not extractable Not extractable N/A 
















activation was statistically significant (p<.001).  No significant change in control 
group. 
Significantly higher patient activation in intervention group compared with 
control group at post-intervention (F=12.5, p<.01). 
Uncontrolled Studies 
Crosby et al. 
(2017) 
Significant improvement in patient activation pre- (Mean (SD) 69.75 (13.17)) to 
post-intervention (Mean (SD) 75.36 (16.03), p=.03) 
 
Hedges g =.38* N/A 
Results not sustained at 6-month 
follow-up 
(F=.911, p=.440, 
Fløde et al. 
(2017) 
Significant improvement in patient activation pre- (Mean (SD) 63.7 (15.3)) to 
post-intervention (Mean (SD) 70.1 (14.0) p<.001) 
Hedges g =.43* N/A 










Kawi et al. 
(2015) 
Significant improvement in patient activation pre- to post-intervention (t (15) 
=4.45, p<.001). 
Hedges g =.81* N/A N/A 
Shah et al. 
(2015) 
Patient activation found to be significantly higher post-intervention; 35 
participants increased patient activation scores by one or more levels, 24 
participants remained unchanged and 1 participant demonstrated lower patient 
activation. Findings were statistically significant (p<.001). 
Not extractable N/A N/A 
Turner et al. 
(2015) 
Significant improvement in patient activation pre- (Mean (SD) 52.2 (12.4) to post-
intervention (Mean (SD) 60.2 (15.8), p .001, d=.65). 
Hedges g =.57* N/A N/A 
Turner et al. 
(2014) 
Significant improvement in patient activation pre- to post-intervention (t=4.02 
(104); p<.001; d=.36). 




Significant improvement in patient activation pre- to post-intervention (t=7.06 
(117), p<.001, d=.81). 
Hedges g =.63* N/A N/A 
Ledford et al. 
(2013) 
Significant improvement in patient activation pre- (Mean (SD) 51.80 (11.78)) to 




















Wallace et al. 
(2009) 
Significant improvement in patient activation pre-post-intervention (t=6.32, 
p<.001, d=.42). 
 
Hedges g =.40* N/A N/A 
 
*Difference in post-intervention scores between intervention and control group; Effect size calculated with Lakens (2013) Version 3.2 
 
Hedges g - a measure of effect size for use with t-test. Effect size estimates as follows: .2 (small); .5 (medium); .8 (large) 
 
Partial η2 - a measure of effect size for use in analysis of variance. Effect size estimates as follows: .01(small); .06 (medium); .14 (large) 
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The main findings and effect sizes related to the PAM-13 are found in Table 5. Out of 25, 21 
studies reported a statistically significant increase in patient activation scores pre- to post-
intervention in those receiving a self-management intervention, of which, six – all RCTs- were 
given the highest rating (++) for methodological quality (Ehde et al., 2015; Grønning et al., 
2012; Lorig et al., 2009; Lorig et al., 2010; Shively et al., 2013; Young et al., 2016). Of the 21 
studies which found a significant increase in activation, eight found a small-medium within-
group effect size (Crosby et al., 2017; Fløde et al., 2017; Grønning et al., 2012; Lorig et al., 
2009; Lorig et al., 2010; Solomon et al., 2012; Turner et al., 2014; Wallace et al., 2009). A 
further eight found medium-large effect sizes (Ehde et al., 2015; Hochhalter et al., 2010; Kawi 
et al., 2015; Kosmala-Anderson et al., 2014; Morrison et al., 2016; Shively et al., 2013; Turner 
et al., 2015; Young et al., 2016). Two found very large effect sizes (Kaltman et al., 2015; 
Ledford et al., 2013). Four studies reported no improvement within or between groups for 
patient activation (Maindal et al., 2010; Rygg et al., 2012; Ryvicker et al., 2013; Titova et al., 
2017), of which, one study (Rygg et al., 2012) was allocated a rating of ‘++.’ 
Solomon et al. (2012) conducted exploratory analyses within the intervention group and 
found that increases in patient activation among ‘highly activated’ patients was significantly 
lower compared with ‘moderately’ and ‘low’ activated patients over time. In another study, 
although no significant increase in patient activation was found pre- to post-intervention 
within or between groups, sub-group analyses revealed participants with poorest diabetes 
control had significantly higher patient activation at post-intervention (Rygg et al., 2012). 
 
SMI vs usual care 
 
Twelve studies evaluated a SMI against a usual care control group, comprising of 11 RCTs 
and 1 non-randomised controlled study. Six RCTs found the SMI group to have significantly 
higher patient activation at post-treatment compared with usual care (Grønning et al., 2012; 
Hibbard et al., 2007; Lorig et al., 2009; Lorig et al., 2010; Morrison et al., 2016; Shively et al., 
2013). Each of these six studies demonstrated small-to-medium between group-effect sizes 
(ranging from 0.17 to 0.47) and all, except one, were allocated the strongest rating (++) of 
methodological rigour. By comparison, six studies did not find significantly higher post-
treatment differences between intervention and usual care groups and all, except one, were 
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given the second highest rating (+) of methodological quality (Hochhalter et al., 2010; Maindal 
et al., 2010; Ryvicker et al., 2013; Titova et al., 2017; Young et al., 2016). While Rygg et al. 
(2012) was allocated a higher methodological quality score of ‘++.’  
  
SMI vs active control 
 
Five studies evaluated the effects of a SMI against an active control. Four were RCTs and one 
was a non-randomised controlled study. Two RCTs found statistically significant differences 
between groups at post-intervention with results favouring the self-management condition 
(Ehde et al., 2015; Solomon et al., 2012). Methodological quality and effect sizes between the 
studies differed; Ehde et al. (2015) demonstrated a medium between-group effect (0.58) and 
was allocated an overall methodological bias rating of ‘++’, while Solomon et al. (2012) found 
a much smaller between-group effect in their study (0.18) and received an overall 
methodological bias rating of ‘+.’ One non-randomised controlled study, evaluated to be on 
the lower range of ‘+’ for methodological rigour, also found a significant between-group 
difference, however, effect sizes were unable to be calculated (Hibbard et al., 2009). Two 
RCTs with a methodological quality rating of ‘+,’ found no significant post-intervention 
changes in activation between the SMI and active control groups (Hochhalter et al., 2010; 
Ryvicker et al., 2013). 
 
Effects at follow-up 
 
Eight studies conducted follow-up analyses. Six studies, five of which received the highest 
methodological quality rating (++), reported that gains in patient activation within the 
intervention group were maintained at follow-up, as expected (Ehde et al., 2015; Grønning 
et al., 2012; Hibbard et al., 2007; Lorig et al., 2009; Lorig et al., 2010; Fløde et al., 2017). 
However, four of these studies also found that patient activation in the control groups 
improved at follow-up to the extent that they found no significant differences between the 
intervention group and comparison group at follow-up. One study reported that 
improvements in patient activation in the intervention group were not maintained at all at 6 
months follow-up, although this study was of relatively poor methodological quality and 
received a rating of ‘-’ (Crosby et al., 2017).








This review aimed to evaluate the effectiveness of SMIs for improving patient activation in 
adults with long-term health conditions compared with other forms of active intervention or 
treatment as usual.  A secondary aim was to evaluate if any positive effects on patient 
activation following intervention were maintained at follow-up. 
 
4.1 Summary of results  
 
The studies included in this review overall found a positive effect of SMIs on patient activation. 
In over half of the studies comparing a SMI with treatment as usual or an active control, the 
positive change in the SMI group was significantly greater than the change that occurred 
within the control group. The methodological ratings of the studies reporting significant 
between-group effects favouring SMIs were deemed overall better quality in contrast with 
studies that did not find significant between-group effects.  
 
Relatively few studies had a follow-up period (n = 8). Out of those that did, the majority (n 
= 6) found that patient activation was maintained within the intervention group at follow-up. 
However, four of these studies also found improvements in the control groups over time, 
meaning that between-group differences (SMI vs. control) were no longer significantly 
different at follow up. Therefore, the impact of SMIs compared with control groups is 
somewhat uncertain. Nonetheless, patient activation gains in the self-management conditions 
were largely maintained at follow-up. 
 
4.2 Quality of the evidence  
 
The overall quality of the studies, with respect to their ability to address the review question, 
was adequate, with sampling, allocation method, intervention variability and inclusion of 
follow-up measures being areas of relative weakness. The representativeness of the 
populations in some of the included studies may be somewhat biased due to convenience 
sampling. In addition, the degree of variation between interventions makes it somewhat 
difficult to assess the internal validity of the results.  
  
An important consideration are mechanisms of change associated with self-management. 
Whilst improved self-management ability is the aim of SMIs, one of the core processes to 
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facilitate this change are the beliefs and attitudinal changes towards acquiring specific skills in 
relation to the LTC (McAllister, Dunn, Payne, Davies & Todd, 2012). The process of 
measuring patient activation may also encourage reflection on these beliefs and attitudes, 
especially for those who may never have previously considered managing their health 
condition as an evolving ‘skill.’ Hence, the process of measurement by itself may have active 
therapeutic elements; this may explain increases in patient activation in some studies.  
 
Most studies reported an increase in patient activation favouring the self-management 
intervention group. In studies that reported positive results, there were large variations 
among pre-post effect sizes. Varied effect sizes may suggest that, although interventions were 
well covered, some components (e.g. communication training/rehearsal with healthcare 
professionals) may be more effective for increasing activation. However, there is a notable 
lack of research in the literature comparing the effectiveness of different active components 
of SMIs. The view that some components of self-management may be more effective than 
others would appear to be supported by the finding that, across RCTs, effect sizes ranged 
from small (.21) (Grønning et al., 2012) to large (.81) (Ehde et al., 2015). Each of these studies 
were considered methodologically robust and all were rated ‘well’ in terms of intervention 
suitability for increasing patient activation. The variation may also suggest that intervention 
delivery, fidelity or heterogeneity of long-term health conditions are important factors 
affecting improvements in patient activation.  
 
Relatedly, effect sizes could be considered in the context of heterogeneity among the 
intensity and format of interventions. On closer examination of the results, there would 
appear to be an overall trend towards larger effect sizes in the individualised treatments 
compared with group treatments. Individualised treatments are more likely to provide a 
greater intensity of professional input and be tailored towards individuals’ self-management 
needs (Barlow et al., 2002), which may explain the larger impact on patient activation 
outcomes. It seems reasonable to expect that the greatest impact on patient activation would 
be evident in interventions providing a high degree of tailoring and professional input. Web-
based interventions displayed a more consistent picture, with moderate effect sizes in the 
intervention group. While this is encouraging at a time where maximising staff time and 
resources is necessary, more studies evaluating web-based interventions in relation to patient 
activation are needed to determine the clinical significance of positive findings and 
maintenance of effects.   
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Given that the PAM-13 attempts to quantify change across four different levels of activation, 
scores should be interpreted with care. It is possible that some people, who showed no 
change in their activation scores, could have moved towards some meaningful shifts in specific 
self-management tasks but changes were subtle or in the process of contemplation. Another 
consideration of change scores on the PAM-13 is research suggesting that the relationship 
between behaviour and attitudes/beliefs is bidirectional rather than causal (De Leeuw, Engels, 
Vermulst & Scholte, 2008). For example, some individuals may have little confidence or belief 
in their ability to self-manage a health condition and, subsequently, demonstrate low 
activation scores. However, their confidence and beliefs are likely to be positively reinforced 
over time via repeated practice of self-management tasks and vice versa.   
 
A high degree of sample bias may explain why no effect was found in some studies. For 
example, one study recruited hospitalised COPD patients with acute exacerbations (Titova 
et al., 2017). It was hypothesised by the authors that it may be unrealistic to expect clinically 
significant improvements in outcomes such as patient activation in older patients with high 
disease severity and diminished quality of life, irrespective of the intervention. Similarly, where 
the sample already has a relatively high proportion of participants with good levels of patient 
activation at baseline, there are likely to be ‘ceiling effects’ with less scope for improvement 
of this outcome, as was the case in the study by Rygg et al. (2012).  
 
Several studies included in this review used participants from a range of illness groups, 
reflecting the transdiagnostic concept of patient activation. Encouragingly, most studies did 
not exclude potential participants with physical health comorbidities. This could be 
considered a strength as many patients with chronic conditions do experience comorbidity 
in real-life setting (Jones, 2010), improving the ecological validity of the results. Within the 
context of different health conditions, defining what patient activation ‘looks like’ is an 
important consideration (Ryvicker et al., 2013). For instance, individuals with asymptomatic 
conditions (e.g. hypertension) might view self-management as less essential and, therefore, 
may be less responsive to SMIs (Ryvicker et al., 2013). Heterogeneity among health conditions 
means that some self-management behaviours may be more important than others may 
across conditions. Considering this, further research should examine specific relationships 
between patient activation and self-management behaviours in specific health conditions. 
 
A further issue is the extent to which the PAM-13 might overlap with measures of self-
management. Although the scale does not measure a specific behaviour, several items of the 
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PAM-13 ask about existing engagement in self-management behaviours. Thus, the PAM-13 
may correlate strongly with some measures of self-management. Consequently, patient 
activation may not be an entirely independent construct that can then be used to predict self-
management. Whilst there may be some potential questions around conceptual overlap with 
patient activation and self-management, this issue does not appear to be portrayed in the 
extant literature and, perhaps, needs further attention. Nonetheless, it is important to 
balance current findings with the evidence linking patient activation with multiple positive 
health, social and economic outcomes (for review see Mukoro, 2012). In addition, one 
longitudinal study found that patient activation scores at baseline were associated with the 
uptake of cancer screening, obesity and smoking behaviour up to two years later; though 
more research is needed to determine a causal relationship between patient activation and 
self-management behaviours (Greene, Hibbard, Sacks, Overton & Parrotta, 2015). 
 
Efforts to develop measurement tools to quantify patient engagement with self-management 
are to be applauded. From a theoretical perspective, further research in this area may enable 
us to delineate the fundamental mechanisms that facilitate self-managing behaviour and the 
working components of interventions that target these mechanisms (Jonkman et al., 2016). 
This could have useful implications for the design of contemporary self-management 
interventions. 
  
4.3 Strengths and limitations of the review  
 
To the authors' knowledge, this review is the first of its kind to assess patient activation, as 
measured by the PAM-13, as a clinical outcome. Traditionally, research trials and systematic 
reviews in disease-management have focused on changes to disease self-efficacy, biological 
markers, symptom burden, quality of life or adherence as key indicators of the effectiveness 
of SMIs. However, these indicators may be too heterogeneous across conditions. Global 
indicators of improvement, such as patient activation, are starting to be used for intervention 
evaluation in chronic health conditions (e.g. Moore et al., 2016). This is in line with policy and 
guidance from The Kings Fund and the Department of Health to support people to self-care 
and to deliver better services for people with LTCs (Coulter, Roberts & Dixon, 2013; DOH, 
2006). In order to demonstrate the applicability and utility of patient activation as a 
transdiagnostic construct, the authors chose a narrative approach to data-synthesis and a 
meta-analysis was not performed in the current review due to the decision to include a 
diverse set of populations and interventions. The main limitation of this review is the degree 
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of heterogeneity among the studies reviewed in terms of both interventions and conditions. 
Consequently, the degree of confidence in results and findings should be interpreted in light 
of this variation. Nonetheless, it is unlikely that future studies further examining the 
conclusions of the present review would be free from heterogeneity.  
 
4.4 Implications for research and practice  
 
Given the constraints on services as to what they can offer patients with LTCs, professionals 
may need to consider if in-service or locally developed SMIs are evidence-based, as well as 
how they might meaningfully evaluate effectiveness. Developing SMIs that aim to enhance 
patients’ confidence, beliefs and attitudes towards acquiring self-management skills (i.e. 
patient activation) may result in effective self-management behaviours which maintain or, 
where possible, improve quality of life (Hibbard et al., 2004). The PAM-13 has good clinical 
utility as an outcome measure to evaluate the impact of SMIs, as activation outcomes have 
been linked to improved self-management and quality of life in a wide range of LTCs (Moore 
et al., 2016).   
 
One of the limitations of the PAM-13 is the licensing cost for use in larger studies, a 
disadvantage if conducting large-scale RCTS. A free research license can be obtained for 
studies aiming to recruit no more than 250 participants. NHS England currently have an 
agreement to use the PAM-13 in an ongoing multi-site evaluation of services as part of their 
commitment to the ‘Five Year Forward View’ policy (NHS England, 2017).  Combining PAM-
13 with the collection of other information on self-management behaviours may enable 
researchers to capture the spectrum of change in areas impacted by SMIs. Given that 
improving this construct may be a precursor for self-management behaviour, a similar review 
evaluating the evidence of patient activation as a mechanism of change in SMIs may be useful.  
Such a review would strengthen the theory and evidence upon which new SMIs are devised 
for different conditions, as well as their successful implementation. Moreover, the current 
review has highlighted that a valuable contribution to the literature would be a review that 
attempts to quantify what changes in activation change may look like across conditions, both 
broadly and specifically. Finally, future research could seek to explore and target some of the 
factors that might predict patient activation in specific conditions to identify clinical 
populations at risk of poor self-management and, subsequently, poor health outcomes. 
Targeting modifiable factors that might affect patient activation could result in more 
efficacious self-management interventions. 
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4.5 Authors’ conclusions   
 
At present, there is currently evidence of a moderate-to-high quality that suggests that self-
management interventions are effective for improving patient activation in long-term 
conditions compared with usual care or other active control groups. There is also preliminary 
evidence that positive effects on patient activation are maintained at follow-up of 3-months 
and beyond. Further randomised controlled studies evaluating self-management and control 
groups at follow-up are needed to strengthen the current evidence. 
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Objectives: In long-term conditions, patient activation has an important influence on self-
management and quality of life. Relatively little is known about the processes associated with 
patient activation in MS. The present study sought to explore relationships between patient 
activation, psychological factors (depression and valued living), perceived clinician empathy, 
perceived MS symptom severity, self-management and demographic variables. It also 
examined whether depression, valued living and perceived clinician empathy are unique 
predictors of activation, and if activation is a unique predictor of self-management for MS, 
when relevant confounding variables are controlled for.  
 
Design: A cross-sectional design was used, recruiting 118 MS patients via a NHS outpatient 
setting. 
   
Methods: Participants completed the short-form Patient Activation Measure, MS Impact 
Scale, Hospital Anxiety and Depression Scale, Engaged Living Scale, Consultation and 
Relational Empathy Measure, MS Self-Management Scale, together with demographic 
information. Correlations and hierarchical regression analyses were used to explore 
relationships between variables.  
 
Results: After controlling for demographic variables and MS symptom severity, only valued 
living was a significant predictor of patient activation. Neither depression nor perceived 
clinician empathy were significant predictors. After controlling for valued living, depression 
and perceived clinician empathy, patient activation predicted 5.5% of variance in self-
management for MS. Both activation and perceived clinician empathy were significant 
predictors of self-management. 
 
Conclusions: Valued living is associated with patient activation in MS, while patient activation 
and perceived clinician empathy are associated with MS self-management. Self-management 
interventions, which target valued living and the patient-clinician relationship, may be effective 
for addressing low levels of activation in some patients with MS. 
 




Multiple Sclerosis (MS) is a progressive and disabling disease involving demyelination of the 
central nervous system, typically diagnosed between the age of 20-40 years old (Brück & 
Stadelmann, 2003). An estimated 127, 000 people live with MS in the UK (Mackenzie, Morant, 
Bloomfield, MacDonald & O’Riordan, 2014). The World Health Organisation (WHO, 2008) 
estimates a global prevalence of 30 per 100, 000, however the range is highly variable across 
continents. Europe is the continent with the highest estimated prevalence (80 per 100,000), 
with the highest rates in the world reported in Scotland (ranging from 145 to 193 per 100, 
000) (Pugliatti, Sotgiu & Rosati, 2002). The condition affects men and women at a ratio of 2:3 
(Thomas, Thomas, Hiller, Galvin, & Baker, 2009). People with MS can face a range of problems 
with mobility, fatigue, pain, cognition and sleep. Alongside physical complaints, MS is often 
associated with high rates of depression, distress, social and relationship difficulties and poor 
quality of life (Dennison, Moss-Morris, Yardley, Kirby & Chalder, 2013). At present, there is 
no known cure; therefore, treatment involves lifelong management of the disease and 
symptoms through medication, therapeutic support (e.g. physiotherapy) and lifestyle 
alterations.  
 
In the context of growing demands on health care services, self-management is a promising 
approach to coping with symptoms associated with MS (Fraser et al., 2013). Self-management 
interventions (SMIs) aim to support people to develop the knowledge, practical skills and 
psychological resilience required to effectively manage the impact of an illness, and maintain 
quality of life (Barlow, Wright, Sheasby, Turner & Hainsworth, 2002). As interest in SMIs 
grows, it has become important to understand the mechanisms that lead individuals to 
become more engaged in managing their health. One psychological construct that has 
received growing attention in self-management concerns individuals’ confidence, attitudes and 
beliefs around acquiring skills and performing self-management tasks, known as “patient 
activation” (Hibbard, Stockard, Mahoney, & Tusler, 2004). 
 
How is patient activation conceptualised and measured? 
  
Patient activation is the extent to which an individual participates in his or her own care and 
illness management (Hibbard et al., 2004). The construct is suggested to reflect patients’ 
knowledge of their condition, commitment to treatment routines, and openness with health 
professionals (Stepleman et al., 2010), and when these components interact, an individual is 
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more likely to be empowered, attuned and responsive towards their own self-care even in 
the face of challenges and limitations of their illness. The short-form Patient Activation 
Measure (PAM-13; Hibbard, Mahoney, Stockard, & Tusler, 2005), the most commonly used 
measure of activation, is a 13-item self-report scale assessing the extent to which individuals 
possess the skills, knowledge and confidence to self-manage. Responses to items such as “I 
am confident that I can follow through on medical treatments I need to do at home” are rated from 
‘strongly disagree’ to ‘strongly agree.’ Scoring is converted to a scale of 0-100, where higher 
scores are indicative of higher levels of patient activation. 
 
Activation is measured across four progressive levels (Hibbard et al., 2004). While formalised 
descriptors are available (see Figure 1: Hibbard et al., 2004), an example of low activation 
(level 1) might be the person who “just follows the doctor’s advice,” such as taking medication, 
though may be forgetful and inconsistent in adherence. At the opposite end of the continuum 
(level 4) are individuals who engage in various health-supporting behaviours to manage their 
own healthcare, recognise the impact of stress on their ability to self-manage and can 
effectively manage this impact via self-monitoring most of the time. 
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The PAM-13 has been utilised to evaluate the outcome of interventions, across a range of 
settings and long-term conditions (LTCs) (Hibbard & Greene, 2013). There is evidence that 
scores on the PAM-13 are associated with positive health outcomes including reduced blood 
glucose, body mass index, cholesterol (Remmers et al., 2009; Rogvi, Tapager, Almdal, Schiøtz, 
& Willaing, 2012; Skolasky, Mackenzie, Wegener, & Riley, 2011) and health-promoting 
behaviours, for example, information seeking, self-management, and lifestyle changes 
(Hibbard et al., 2004; Hibbard et al., 2005; Hibbard, Mahoney, Stockard & Tusler, 2007). 
While NHS England policy has begun to support the use of PAM, robust evidence of its 
suitability and effectiveness in UK populations with LTCs has yet to develop and be circulated 
nationally (Roberts et al., 2016). Regarding the utility of the PAM-13 in a UK context, it is 
further highlighted that little is known about sociodemographic and clinical variables that may 
predict activation. One underpowered pilot study identified in the review by Roberts et al. 
(2016) explored patient activation and associated sociodemographic and clinical variables in 
a COPD population. It found no significant predictive relationships between gender, disease 
severity, COPD classification and patient activation, although, this conclusion may be 
explained by the small sample size (n = 40) and poor quality of the sample selection and 
recruitment, rather than the absence of any associations. 
 
Evidence of patient activation as a predictor of self-management 
 
There is evidence that the beliefs individuals hold in relation to their illness, appraisals of the 
challenges they face, and coping skills are all associated with levels of adjustment to their 
condition and wellbeing, and that these factors may act as a buffer against poor health 
outcomes (Dennison, Moss-Morris & Chalder, 2009). Lubetkin, Lu and Gold, (2010) found 
greater self-rated patient activation was related to better self-rated health among a general 
adult primary care population, while Goodworth et al. (2016) found a significant positive 
relationship between patient activation and outcomes of self-efficacy and quality of life in MS 
patients.  
 
Moreover, interest in enhancing patient activation in chronic illness groups is growing as 
services strive to empower patients to take a more active stance in decisions and actions 
regarding their health. In a large trial involving 479 patients with a chronic illness randomly 
allocated to either a SMI or no intervention control group, positive change in patient 
activation was associated with greater uptake of health-promoting behaviours including 
regular exercise, stress management, and increased attention to dietary fat (Hibbard et al., 
Page 64 of 147 
 
2007). However, the authors found that the control group also improved on these outcomes 
and, as they did not control for potential confounding variables in their study (e.g. gender or 
disease severity), it is difficult to infer what factors may have influenced the differences 
between the groups. Several studies have demonstrated that symptom severity and gender 
are factors that may influence self-management (DiMatteo, Haskard, & Williams, 2007; Kerr 
et al., 2007; Manteuffel et al., 2014). A study by Rask et al. (2009) found that patient activation 
was positively correlated with disease-specific self-management activities including glucose 
testing, foot checks and eye examinations in diabetic patients. Whilst this is encouraging, most 
patients in this study were female, African-Americans and ceiling effects were observed as a 
large number of patients demonstrated high levels of activation at baseline; thus, the ability 
to generalise positive disease-specific outcomes from this study may be limited.  
 
Most studies of the relationship between patient activation and self-management are cross-
sectional, however, longitudinal studies examining whether patient activation predicts health 
behaviours have been reported (Greene, Hibbard, Sacks, Overton & Parrotta, 2015; 
Remmers et al., 2009). One study found that greater patient activation in diabetic patients 
was positively associated with future biomarkers of diabetes control (Remmers et al., 2009). 
A more recent study demonstrated that patient activation scores at baseline were associated 
with the uptake of cancer screening, obesity and smoking behaviour up to two years later 
(Greene et al., 2015). Although more longitudinal studies are needed, these findings indicate 
the possible value of patient activation in predicting health outcomes and the need to 
understand the factors that may put some patients at risk for lower levels of activation.  
 
What variables might predict patient activation in MS? 
 
Sociodemographic variables and depression 
 
Research by Stærk (2015) supports the view that levels of activation observed in people with 
MS appear to be largely in line with levels of patient activation in other conditions (e.g. 
diabetes, cancer) as reported by Hibbard & Cunningham (2008). Goodworth et al. (2016) 
have suggested that the activation levels of MS patients could be affected by the 
unpredictability of MS relapse and progression, and that reliance on relationships with 
healthcare providers may differ somewhat from other LTCs. To date, only one study has 
explored potential predictors of patient activation in MS (Goodworth et al., 2016). This study 
found that patient activation was negatively associated with depression and positively 
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associated with quality of life and MS self-efficacy. It was also reported that education, 
perceived functioning, depression and MS self-efficacy were unique predictors and accounted 
for 35 percent of the variance associated with patient activation (Goodworth et al., 2016). 
 
One surprising outcome of the study by Goodworth et al. (2016) was that, although a positive 
relationship was observed between activation and medication adherence in MS, the 
relationship did not reach significance as found in other studies (Bodenheimer, Wagner & 
Grumbach, 2002; Forbat, Cayless, Knighting, Cornwell, & Kearney, 2009). When exploring 
variables that may exert an influence over patient activation in MS; other variables need to 
be considered. One limitation of the study by Goodworth et al. (2016) is that the authors 
did not include a measure of self-management. Further studies should seek to examine if any 
relationship exists between patient activation and self-management in MS as, thus far, only a 




Acceptance and Commitment Therapy (ACT; see Hayes, Strosahl & Wilson, 1999 for full 
details) is an increasingly popular treatment for psychological problems in the context of 
LTCs. The aim of ACT is to coach individuals to work towards acceptance of personal 
struggles, orientate to their own values and take actions towards what is important to them 
– known as ‘valued living’ (Sheppard, Forsyth, Hickling & Bianchi, 2010). ACT entails the use 
of experiential exercises (e.g. defusion practice and identifying personal values), metaphors 
and behavioural principles (e.g. graded exposure) to facilitate emotion regulation and positive 
behavioural changes in accordance with personal values (Sheppard et al., 2010). Interest is 
growing regarding the role of valued living in LTCs. There is evidence that brief ACT 
interventions are successful for promoting symptom reduction and quality of life people with 
diabetes (Gregg, Callaghan, Hayes & Glenn-Lawson, 2007), epilepsy (Lundgren, Dahl & Hayes, 
2008) and MS (Nordin & Rorsman, 2012). A study by Ferenbach, Gillanders and Harper (2011) 
found that ACT processes (i.e. cognitive fusion and acceptance) were stronger mediators of 
adjustment to MS than the content of cognitions (i.e. illness appraisals). Ferenbach et al. (2011) 
did not examine the role of valued living in adjustment to MS, but there is evidence that 
promoting valued living is important in the wider LTC literature. Lundgren et al. (2008) found 
evidence that valued living mediated seizure activity and quality of life outcomes in depressed 
epilepsy patients; while Ciarrochi, Fisher and Lane (2011) have shown that valued living was 
related to improved wellbeing and reduced distress in a sample of cancer patients. Such 
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studies provide preliminary evidence that valued living is meaningful for quality of life and 
management of adverse symptoms and, therefore, may be an important process in activation. 
As such, there would appear to be a reasonable basis on which to propose valued living may 
be associated with patient activation in an MS population. 
 
The patient-clinician relationship 
 
Effective patient-clinician communication is required for self-management processes, such as 
presenting to healthcare providers for routine care or adhering to treatment 
recommendations from professionals (Rieckmann et al., 2015). For example, Remington, 
Rodriguez, Logan, Williamson and Treadaway (2013) report that the quality of the 
therapeutic relationship is important in conditions like MS, and that there is greater 
adherence to treatment recommendations in those who perceive effective communication 
with their healthcare provider. Patient definitions of quality care suggest that empathy is a 
key factor underpinning perceptions of effective communication (Lewis, 1994). Empathy in 
clinical consultations involves the clinician’s ability to convey an accurate understanding of 
the patient’s perspective and feelings, and to respond helpfully to the needs of the patient 
(Mercer, Maxwell, Heaney & Watt, 2004). In some cases, clinicians may be the primary source 
of support for individuals with LTCs (Tang, Brown, Funnell & Anderson, 2008). It has been 
suggested by Mercer and Reynolds (2002) that clinician empathy improves patients’ ability to 
understand their illness, enables patients to better-manage their health conditions and leads 
to better outcomes; however, there is a notable lack of research into the role of empathy in 
clinical outcomes. Further exploration of the role of empathy in the clinical encounter would 




Collectively, research suggests that patient activation has an important influence on self-
management for LTCs. However, relatively little is known about which processes are 
associated with activation in MS. Understanding the processes linked to effective self-
management is especially important as MS clinicians rely on patients being self-directed and 
responsive to maintain and prolong good health status and quality of life. A study to explore 
relationships and investigate the predictive value of potentially modifiable variables related to 
activation in this population would be a useful expansion of the literature. Further clarifying 
these relationships could serve to identify which groups might be at risk for low activation, 
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what potential targets for treatment might be, and to better understand the value of and 
limitations of patient activation as a way of conceptualising and promoting self-management 
in MS. 
 
1.1 Aims of the current study 
 
The main aim was to (1) explore whether patient activation is related to psychological factors 
(depression and valued living), perceived clinician empathy, perceived MS symptom severity, 
MS self-management and demographic factors (age, gender and level of education), (2) 
examine whether psychological factors (depression and valued living) and perceived clinician 
empathy may predict patient activation when other relevant factors are controlled for and 
(3) examine whether patient activation may predict MS self-management when other 
confounding variables are controlled for.  
 
Hypothesis 1: Patient activation will be negatively correlated with age, perceived symptom 
severity and depression; and positively associated with level of education, perceived clinician 
empathy, valued living and MS self-management. 
 
Hypothesis 2: Psychological factors (depression, valued living) and perceived clinician empathy 
will be significant predictors of patient activation when other predictive demographic and 
clinical variables are controlled for. 
 
Hypothesis 3: Patient activation will be a significant predictor of MS self-management when 
other predictive variables are controlled for.








2.1 Design  
 
We employed a cross-sectional, questionnaire-based design to examine relationships 
between patient activation, perceived MS symptom severity, clinician empathy, depression, 
valued living, demographic information and self-management for MS.  
 
The NHS South West Exeter Research Ethics Committee granted ethical approval and site-
specific approval was obtained from the NHS Lothian Research and Development 






Adults aged ≥18 years with a diagnosis of MS, according to ICD-10 criteria, given by a 
neurologist were eligible to participate. Those with cognitive impairment or insufficient 
understanding of the English language that would affect their ability to give informed 




During the period of April to November 2017, a consecutive series of 153 participants 
attending the Anne Rowling Regenerative Neurology Clinic, Edinburgh, UK were invited to 
participate. One hundred and eighteen individuals returned the questionnaire packs 
(response rate = 77%) to the Anne Rowling Clinical Research Facility. Non-identifiable 
demographic information was collected to establish the characteristics of the sample.
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2.3 Measures  
 
Demographic Questionnaire: participants provided non-identifiable demographic data (age 
category, gender, level of education, MS type, length of diagnosis and use of Disease Modifying 
Therapies). 
 
The Patient Activation Measure (PAM-13; Hibbard et al., 2005): contains 13 items assessing 
patient activation, that is, the skills, knowledge and confidence to manage an illness. Responses 
to items such as “I am the person who is responsible for taking care of my health” are rated from 
“strongly disagree” to “strongly agree.” Scoring is converted to a scale of 0-100, where higher 
scores indicate higher levels of patient activation. The scale exhibits strong construct, 
convergent, discriminant and predictive validity and high internal reliability across several 
illness groups (Hibbard et al., 2005), including MS (α = .88) (Stepleman et al., 2010). 
Cronbach’s alpha for the PAM-13 in the current study was .86.  
 
The ‘Physical’ subscale of the Multiple Sclerosis Impact Scale (MSIS-29; Hobart, Lamping, 
Fitzpatrick, Riazi & Thompson, 2001): a 20-item self-report subscale measuring the severity 
of physical symptoms of MS. The MSIS-29 also comprises of one other 9-item subscale 
measuring ‘psychological’ symptoms of MS. For the current study, only the ‘physical’ subscale 
was used in analyses. Statements are rated on a 5-point Likert scale from 1 (not at all) to 5 
(extremely) and pertain to the patient’s experience of MS symptoms. Hobart et al. (2001) 
report the MSIS-29 physical subscale displays low floor and ceiling effects, good levels of 
variability and excellent test-retest reliability (r ≥ .87) and internal consistency (α ≥ .91) in 
individuals with both relapsing-remitting and progressive types of MS. Cronbach’s alpha for 
the MSIS-29 ‘physical’ subscale in the current sample was .96. 
 
The ‘Valued Living’ subscale of the Engaged Living Scale (ELS; Trompetter et al., 2013): a 10-item 
subscale assessing individuals’ awareness and familiarity with their values, and the actions 
taken by the individual towards those values, as conceptualised by Acceptance and 
Commitment Therapy (ACT). The ELS contains one other 6-item subscale measuring ‘life 
fulfilment.’ Only the ‘valued living’ subscale was used in the analyses of the current study. 
Responses range from “completely disagree” to “completely agree” on a 5-point Likert scale, 
with higher scores indicative of greater engagement with values. The ‘valued living’ subscale 
of the ELS shows very good internal consistency (α = .87) and validity has been demonstrated 
by significant correlations with theoretically related process and outcome variables such as 
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psychological distress, mindfulness, and psychological flexibility (Trindade, Ferreira, Pinto-
Gouveia & Nooren, 2016; Trompetter et al., 2013). Cronbach’s alpha for the ELS ‘valued 
living’ subscale in the current sample was .87. 
 
The ‘Depression’ subscale of the Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 
1983): a 7-item subscale measuring depressive symptomology. The HADS also contains 
another 7-item subscale assessing anxiety symptoms. Only the ‘depression’ subscale was used 
in analyses for the current study. Responses range from 0-21 and higher scores indicate 
greater levels of depression, with established cut-offs of ‘normal’ (0-7); ‘mild’ (8-10); 
‘moderate’ (11-14); and ‘severe’ (15-21) (Stern, 2014). The ‘depression’ subscale of the HADS 
has acceptable reliability (α = .77) (Crawford, Henry, Crombie & Taylor, 2001). It has also 
been validated in previous research in MS (Honarmand & Feinstein, 2009; Spain, Tubridy, 
Kilpatrick, Adams & Holmes, 2007). Cronbach’s alpha for the HADS ‘depression’ subscale in 
the current sample was .84. 
 
The Consultation and Relational Empathy measure (CARE; Mercer et al., 2004): assesses 
perceptions of MS clinician communication and empathy in the consultation. The measure 
comprises 10 items such as “how was the doctor at showing care and compassion” rated on a 5-
point Likert scale from 1 (poor) to 5 (excellent), with scores ranging from 10-50. Higher 
scores indicate greater perceived empathy. The measure has shown high internal reliability, 
with a Cronbach’s alpha of .93 (Mercer et al., 2004) and has demonstrated validity in both 
doctor and nursing consultations (α = .97) (Bikker, Fitzpatrick, Murphy & Mercer, 2015). 
Validation for use between different professional groups was a relevant consideration in the 
current study as both doctors and nursing staff lead MS consultations. Scores have also been 
found to be unrelated to age, gender, employment and self-reported general health (Bikker 
et al., 2015). Cronbach’s alpha for the CARE in the current study was .97. 
 
The Multiple Sclerosis Self-Management Scale Revised (MSSM-R; Bishop & Frain, 2011): 
comprises 24 items assessing self-management knowledge and behaviours in adults with MS. 
Ratings are made on a scale from 1 (disagree completely) to 5 (agree completely), with higher 
scores indicating better self-management. The scale has been criticised for lacking possible 
additional self-management items relevant for MS (Ghahari, Khoshbin & Forwell, 2014); 
however, it is the only measure that attempts to quantify self-management in those with this 
condition. The measure has been used in a previous postal survey in MS, demonstrates high 
internal consistency (Cronbach’s α = .85), satisfactory to good test-retest reliability, 
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moderate to high criterion validity for the factor structure against well-established measures, 
and moderate face validity (Ghahari et al., 2014; Wilski, Tasiemski & Kocur, 2015). 




Neurologists and specialist MS nurses in the Anne Rowling Clinical Research Facility 
approached potential participants about the study at the end of their consultation. Individuals 
expressing an interest in the study were invited to speak with a researcher in the facility (see 
Appendix F for study protocol). The researcher gave further details and provided people 
with packs containing a study information sheet (Appendix G), a study consent form 
(Appendix H), and the seven outcome measures (Appendix I). Contact details were 
requested to discuss participation after a ‘cooling off’ period and individuals were invited to 
take the packs home and consider whether they would like to complete the questionnaires 
and post them back to the researcher. A pre-paid envelope was included in the research pack. 
Consent to participate was provided by the return of the research questionnaires with or 
without the study consent form. Questionnaires and consent forms were separated upon 
return and marked with a unique identifier code.  
 
2.5 Statistical analysis  
 
Statistical analyses were conducted using IBM SPSS Statistics for Windows (Version 23) (IBM 
Corporation, 2015). Prior to statistical analysis, missing data and parametric assumptions 
were explored. Descriptive statistics for key variables were presented. T-tests were 
conducted to determine any differences between gender in relation to the outcome variables 
of patient activation and MS self-management. Correlational analyses were conducted for all 
key variables to ascertain relationships. For variables where relationships were significant, 
regression analyses were conducted with depression, perceived clinician empathy and valued 
living as independent variables, and patient activation and MS self-management as dependent 
variables. The data was examined to ensure no violation of regression assumptions including 
homoscedasticity, multicolinearity, linear relationships between predictor and outcome 
variables and normal distribution of residuals.  
 
2.5.1 Power and sample size 
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Power analyses were conducted to determine the sample size required for the study. The 
relationships between valued living, clinician empathy and patient activation had not 
previously been studied; however, a previous study found a moderate correlation between 
depression and patient activation in MS patients (r = .43). Therefore, a medium effect size 
was anticipated. Using G*Power (version 3.0.10; Faul, Erdfelder, Buchner, & Lang, 2009) to 
detect a medium effect at .8 power at alpha level of .05, with seven independent variables 
(gender, age, level of education, MS symptom severity, depression, clinician empathy and 
valued living) and one dependent variable (patient activation), a sample size of 103 was 
required. 
 
2.5.2 Missing data  
 
Missing data items were analysed. Little’s Missing Completely at Random (MCAR) Test 
indicated non-significance for all individual subscales and the entire dataset (χ² (3488) = 
3520.14, p = .35). Expectation Maximisation (EM) was therefore employed to input missing 
data, in situations where ≤20 percent of data per case per subscale were missing. The EM 
method has a large body of empirical support and is reported to be superior to other 
imputation methods, as it requires a less stringent assumption about the missing data 
mechanism (Enders, 2011). Where >20 percent of data were missing per case per scale, the 
scale was excluded from analyses. 
 
2.5.3 Tests of reliability  
 
Cronbach’s alpha tests of internal consistency were calculated for key variables and subscales. 
Values >.7 are generally considered to suggest adequate levels of reliability (Field, 2018). 
Within this study, reliability for all subscales and scales ranged from .82 (MSSM-R) to .97 
(CARE), indicating good to excellent reliability.  
 
2.5.4 Data analysis  
 
Data were initially examined for outliers, levels of skewness and kurtosis. Histograms and 
box plots indicated some outliers in the data for PAM, CARE and MSIS-Physical scales. 
Outliers were corrected by the process of winsorizing which involves replacing extreme 
scores with a score 3 standard deviations from the mean, as recommended in Field (2018). 
On visual inspection, all variables were found to be reasonably normally distributed except 
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for the CARE scale and the MSIS-Physical subscale; however, Kolmogorov-Smirnov tests at 
p > 0.05 indicated a degree of non-normality (skewedness) in the PAM, CARE, MSIS-Physical 
and HADS-Depression scales. The Kolmogorov-Smirnov test has been criticised by some 
researchers for detecting significant results for small, unimportant effects in large samples 
(Field, 2018), however, in the current study converging evidence of non-normality was found 
in the distribution plots for two variables (CARE and MSIS-Physical). A bootstrapping 
procedure was, therefore, used in subsequent inferential analyses to correct for non-
normality. Bootstrapping is a widely recognised statistical procedure to estimate statistical 
parameters (e.g. the population mean and its confidence interval) in samples indicating non-
normality by way of resampling with replacement (Efron & Tibshirani, 1993; Field, 2018; Ong, 
2014). Pearson correlations were calculated for all predictor variables to test for 
multicollinearity. All variables appeared to be appropriate for inclusion in further analyses as 
no extremely high correlations (0.9) were found. 
 
2.5.5 Testing key hypotheses 
 
Hypothesis 1: independent t-tests were used to test for gender differences in patient activation 
and MS self-management. Bootstrapped Pearson correlations based on 2000 samples were 
utilised to investigate the relationships among patient activation, MS self-management, 
psychological factors (depression and valued living), perceived clinician empathy, MS symptom 
severity, and demographic factors (age and level of education).  
  
Hypothesis 2: hierarchical regression analyses using a bootstrapped estimation approach with 
2000 samples was utilised to examine the predictive power of depression, clinician empathy 
and valued living in relation to patient activation when controlling for other potentially 
predictive demographic and clinical variables.  
 
Hypothesis 3: a second hierarchical regression analyses was undertaken to examine the 
predictive power of patient activation in relation to MS self-management when controlling 
for other potentially predictive variables. 
 




3.1 Descriptive data 
 
Demographic and clinical characteristics for the sample are presented in Table 1. A total of 
118 questionnaire packs were returned with a response rate of 77 percent. Of the returned 
questionnaires, one participant returned completed questionnaires without demographic 
information; therefore, whilst the final sample was 118, demographic and clinical data for 117 
participants are presented. Seventy-six individuals (65%) were female and 41 (35%) were male. 
For age category, the largest proportion of participants were between 45-54 years old 
(32.5%), followed by 35-44 years (25.6%). All participants except one indicated they were 
white Caucasian. College or vocational certificate was the level of education most commonly 
completed (30.8%), followed by high school (28.2%), then undergraduate degree (21.4%). 
Regarding MS type, 90 individuals (76.9%) had a diagnosis of relapsing-remitting MS, 18 (15.4%) 
had a diagnosis of secondary progressive MS and five (4.3%) had a diagnosis of primary 
progressive MS. Four individuals (3.4%) were uncertain of their MS type. The most commonly 
reported time category since diagnosis was between 1-5 years ago (30.8%), followed by 6-10 
years ago (22.2%). Seventy-three (62.4%) individuals were taking Disease Modifying Therapies 
(DMT) for their MS and 44 (37.6%) were not. Table 2 presents overall sample means and 
standard deviations for key variables used in the study. 
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Table 1. MS sample demographic and clinical and characteristics   
 n % 
Sample 117 100 

































College / vocational certificate 
Undergraduate degree 
Masters level postgraduate degree 
Doctoral/PhD level postgraduate degree 






























Time since diagnosis 





More than 20 years 
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Table 2. Descriptive statistics for key variables with comparative data 
Scale Scale Value 
Range 
95% Confidence Interval 
Upper              Lower 
Mean (SD) Comparative Data 
Mean (SD) 
Patient Activation (PAM-13) 0 -100 57.05 61.38 59.24 (11.75) 63.18 (11.87)
a
 
MS symptom severity (MSIS-29-physical subscale) 0 - 100 27.60 36.49 31.81 (23.69) 56.0 (27.0)
b
 




Depression (HADS-depression subscale) 0 - 21 4.17 5.55 4.85 (3.67) 5.26 (SD 4.05)
d
 




MS self-management (MSSM-R) 24 - 120 98.65 102.39 100.57 (10.42) 100.98 (11.59)
f
 
CARE: Consultation and Relational Empathy measure; ELS: Engaged Living Scale; HADS: Hospital Anxiety and Depression Scale; MSIS: Multiple Sclerosis Impact Scale; MSSM-
R: Multiple Sclerosis Self-Management Scale revised; PAM-13: Patient Activation Measure  
a From Stepleman et al. (2010); 
b From Jones et al. (2013); 
c Chronic pain sample (M = 35.42, SD = 6.40) from Trompetter et al. (2013); 
d From Honarmand & Feinstein (2009); 
e Mixed LTCs sample (diabetes, coronary heart disease, chronic obstructive pulmonary disease) (M = 45.9, SD = 5.9) from Bikker et al. (2015); 
f From Bishop & Frain (2011). 
 
Means, standard deviations and 95% bias corrected, and accelerated confidence intervals based on 2000 bootstrap samples
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3.2 Control variables 
 
Two-tailed t-tests were conducted to compare gender scores for patient activation and MS 
self-management. Females scored significantly higher (M = 61.41, SD = 12.06) than males (M 
= 55.18, SD = 10.09; t (107) = 2.71, p = .004, two-tailed) for patient activation. The magnitude 
of the difference in the means (mean difference = -6.23, 95% CI: -2.06, -10.36) was moderate 
(Cohen’s d = .56). No significant gender differences were observed for MS self-management. 
Significant gender differences found in relation to patient activation suggested that gender 
should be controlled for in hierarchical regression analyses where patient activation was the 
dependent variable. 
 
3.2.1 Correlation analyses 
 
The relationships between patient activation, age, education, MS symptom severity, 
depression, perceived clinician empathy, valued living and MS self-management were explored 
(see Table 3). As the preliminary Q-Q plots and Kolmogorov-Smirnov tests indicated 
potential non-normality in some of the variables (see section 2.5.4), all correlation analyses 
were bootstrapped. Statistically significant inverse relationships were found between patient 
activation and age (r = -.16, p = .05), MS symptom severity (r = -.46, p < .00) and depression 
(r = -.40, p < .00). Statistically significant positive relationships were observed between patient 
activation and level of education (r = .22, p = .01), perceived clinician empathy (r = .31, p 
< .00), valued living (r = .47, p < .00) and MS self-management (r = .43, p < .00). For MS self-
management, statistically significant positive correlations were observed for clinician empathy 
(r = .44, p < .00) and valued living (r = .36, p < .00). The relationship between self-management 
and depression was not statistically significant, but approached significance (r = -.16, p = .06). 
According to Cohen (1988), the results overall suggest small to moderate correlations 
between variables, with all variables significantly correlated in the predicted directions. 
Significant relationships between patient activation and age, level of education and symptom 
severity suggested these variables should be controlled for in the subsequent hierarchical 
regression analyses where patient activation was the dependent variable (see Table 4). 
Likewise, variables demonstrating significant or near-significant relationships with MS self-
management (depression, clinician empathy and valued living) were controlled for in the 
second regression analyses with MS self-management as the dependent variable (see Table 
5). 
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1. Patient Activation -.16* .22* -.46** .31** .47** -.40** .43** 
2. Age  -.24** .20* -.21* .17* .00 -.14 
3. Level of Education   -.25** .15 -.06 -.11 .06 
4. MS Symptom Severity 
(physical) 
   -.31** -.31** .67** -.07 
5. Clinician Empathy     .25** -.14 .44** 
6. Valued Living      -.50** .36** 
7. Depression       -.16 
 
Based on 2000 bootstrap samples 
 
* Correlation is significant at 0.05 level (one-tailed); ** Correlation is significant at the 0.01 level (one-tailed) 
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3.3 Regression analyses 
 
Separate hierarchical regression analyses were employed to assess the relative ability of 
depression, perceived clinician empathy and valued living measures (HADS-depression, CARE 
and ELS-Valued Living, respectively) to predict patient activation (PAM-13), and the ability of 
patient activation (PAM-13) to predict MS self-management (MSSM-R). Variables that 
demonstrated significant relationships with patient activation (gender, age, level of education 
and symptom severity) and MS self-management (depression, clinician empathy and valued 
living) in the bivariate analyses (see Table 3) were controlled for in the subsequent 
multivariate analyses. The two regression models are presented in Tables 4 and 5.  
 
Predicting patient activation  
 
In the first regression model, data met the assumption of independent errors (Durbin-
Watson = 2.1) and multi-collinearity was not deemed to be a concern as tolerance scores 
ranged from .45 to .92 and variance inflation factor (VIF) scores from 1.08 to 2.20 (Pallant, 
2016). Gender, age, level of education and MS symptom severity were entered at step 1, 
explaining 25% of the variance in patient activation. After entry of depression, perceived 
clinician empathy and valued living at step 2, the total variance explained by the model was 
39%, F (7, 97) = 8.86, p < .00. Depression, perceived clinician empathy and valued living 
explained an additional 14% of the variance in patient activation after controlling for gender, 
age, level of education and symptom severity, R squared change = .14, F change (3, 97) = 7.39, 
p < .00. In the final model, only one of the variables was statistically significant, with valued 
living recording a higher beta value (beta = .37, p < .00) than depression (beta = -.04, p = .71) 
and perceived clinician empathy (beta = .07, p = .43). The positive co-efficient indicates that 
higher levels of valued living were associated with higher patient activation. Coefficients for 
all variables, including those with a non-significant contribution to the model, are presented 
in Table 4.  
 
Predicting MS self-management  
 
For the second regression analyses, data met the assumption of independent errors (Durbin-
Watson = 2.2) and multi-collinearity was not deemed to be a concern as tolerance scores 
ranged from .63 to .94 and variance inflation factor (VIF) scores from 1.05 to 1.5. Depression, 
perceived clinician empathy and valued living were entered in step 1 and explained 27.5% of 
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the variance in MS self-management. After entry of patient activation at step 2, the total 
variance explained by the model was 33%, F (4, 106) = 13.03, p < .00. Patient activation 
explained an additional 5.5% of the variance in MS self-management after controlling for 
depression, perceived clinician empathy and valued living, R squared change = .06, F change 
(1, 106) = 8.70, p < .00. In the final model, two of the variables were statistically significant, 
with perceived clinician empathy recording a higher beta value (beta = .34, p < .00) than 
patient activation (beta = .28, p = .01). Higher levels of perceived clinician empathy and patient 
activation were both associated with greater MS self-management as indicated by positive 
coefficients. Coefficients for all variables are presented in Table 5. 
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Table 4. Summary of hierarchical regression to predict patient activation 
 
Variable B 95% CI 





R R2 R2change 
Step1 .50 .25 .25 
Gender 3.79 -.61 8.13 .16 1.70 .07    
Age -.57 -2.06 1.09 -.06 -.68 .51    
Level of Education 1.06 -.82 2.87 .10 1.09 .24    
MS Symptom Severity (physical)  -.19 -.27 -.11 -.38 -3.99 <.00**    
Step 2 .63 .39 .14 
Gender 3.21 -.61 6.97 .13 1.54 .10    
Age -1.37 -2.77 .21 -.15 -1.69 .08    
Level of Education .91 -.78 2.45 .08 1.02 .28    
MS Symptom Severity (physical)  -.10 -.21 .02 -.21 -1.76 .07    
Depression -.13 -.83 .47 -.04 -.35 .71    
Valued Living .74 .39 1.13 .37 3.87 <.00**    
Clinician Empathy .13 -.23 .46 .07 .81 .43    
 
Clinician empathy measured by the Consultation and Relational Empathy Measure (CARE); Depression measured by the Hospital Anxiety and Depression Scale (HADS); MS 
symptom severity measured by the Multiple Sclerosis Impact Scale (MSIS-29); Valued living measured by the Engaged Living Scale (ELS). 
* Correlation is significant at 0.05 level; ** Correlation is significant at the 0.01 level 
95% bias corrected, and accelerated confidence intervals based on 2000 bootstrap sample
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Table 5. Summary of hierarchical regression to predict MS self-management 
Variable B 95% CI 
Lower    Upper 
Beta 
Standardised 
t P-Value R R2 R2change 
Step1 .52 .27 .27 
Valued Living .46 .16 .78 .27 2.74 .01**    
Clinician Empathy .63 .33 .94 .39 4.71 <.00**    
Depression .03 -.48 .56 .01 .12 .89    
Step 2 .57 .33 .06 
Valued Living .29 -.02 .65 .17 1.71 .09    
Clinician Empathy .53 .24 .84 .34 4.01 .00**    
Depression .18 -.31 .69 .06 .69 .48    
Patient Activation .25 .10 .42 .28 2.95 .01**    
 
Clinician empathy measured by the Consultation and Relational Empathy Measure (CARE); Depression measured by the Hospital Anxiety and Depression Scale (HADS); Patient 
activation measured by the Patient Activation Measure (PAM-13); Valued living measured by the Engaged Living Scale (ELS). 
* Correlation is significant at 0.05 level; ** Correlation is significant at the 0.01 level 
95% bias corrected, and accelerated confidence intervals based on 2000 bootstrap sample 








The current study had three aims: to explore the demographic, psychological and MS-related 
factors associated with patient activation; to determine the role of depression, valued living 
and perceived clinician empathy as relative predictors of patient activation; and to evaluate 
the extent to which patient activation is an independent predictor of MS self-management. 
 
4.1 Summary of findings 
 
Results from the current study provide insight into some of the factors that may influence 
patient activation and self-management in MS. Participants’ level of activation and MS 
symptom severity were lower in the current study than reported in other MS studies (Ehde 
et al., 2015; Jones et al., 2013; Stepleman et al., 2015). Self-management for MS was consistent 
with that reported in a previous MS study by Bishop and Frain (2011). Depression symptoms 
were indicated in 23% of the current sample, which is comparable to the reported point 
prevalence of depression in 20-40% of people with MS in clinical settings (Schippling et al., 
2016). Overall, scores from key variables suggest that the study sample was representative 
of a MS population. Self-reported MS symptom severity may have been lower in this sample 
due to the greater proportion of patients with relapsing-remitting than progressive MS. Rates 
of MS type in the current study are largely in line with figures reported elsewhere (Compston 
& Coles, 2008; Goodworth et al., 2016). Lower patient activation levels observed could 
potentially reflect greater representativeness in the current sample. Less representative 
samples are likely to have a greater bias towards better-educated participants, who in turn 
are likely to have higher activation (Hibbard et al., 2004). In the current study, 
demographic information suggests that around 60 percent of participants were educated to 
high school or college level. Moreover, the high response rate in the current study (77%) 
provides further evidence of sample representativeness. 
 
Variables associated with patient activation 
 
Greater activation was related to gender, higher education, valued living, perceived clinician 
empathy, and self-management. Women demonstrated higher activation scores than men in 
the current study. These findings are in line with previous research that suggests that 
activation is higher in individuals who are better educated and female (Bos-Touwen et al., 
2015; Chubak et al., 2012; Goodworth et al., 2016; Rask et al., 2009). The negative 
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relationships observed between activation, age, depression and perceived severity of MS 
symptoms were also consistent with the results of previous research (Blakemore et al., 2016; 
Goodworth et al., 2016). Titova et al. (2017) has suggested that lower patient activation in 
older patients may be linked to higher disease severity with age. Cohort differences may also 
exist with older patients, as research suggests that older adults demonstrate a greater 
external locus of control and defer more to their healthcare provider to manage and oversee 
their health (Schneider et al., 2006). A significant positive relationship was observed between 
patient activation and self-management for MS in the current study (e.g. medication 
adherence; taking breaks when tired; and discussing symptoms/treatment decisions with MS 
clinicians). This finding is consistent with a body of research indicating a positive association 
between activation and self-management behaviours in the wider literature for LTCs 
(Hibbard et al., 2007; Marshall et al., 2013; Rask et al., 2009). 
 
Predicting patient activation 
 
Valued living was a significant predictor of patient activation after controlling for gender, age, 
level of education and MS symptom severity. This finding is consistent with previous research, 
which suggests that valued living may predict or mediate important health-related outcomes, 
such as psychological distress in cancer and seizure activity in epilepsy (Ciarrochi et al., 2011; 
Lundgren et al., 2008). Our findings indicate that being in contact with personal values and 
having the ability to take actions in line with these values is likely to promote positive 
adaptation when faced with adverse health conditions.  
 
The finding that depression and perceived clinician empathy were not significant predictors 
in our study contrasts with previous research (Alexander, Hearld, Mittler & Harvey, 2012; 
Goodworth et al., 2016). In their study, Goodworth et al. (2016) found that depression did 
explain variance for patient activation in MS. However, their study utilised the Beck 
Depression Inventory, version 2 (BDI-II; Beck, Steer & Brown, 1996) to measure depression 
and, therefore, it may be that depression scores were overestimated in the Goodworth et 
al. (2016) study. The use of the BDI-II in physical illness populations has been criticised due 
to the inclusion of somatic items (e.g. fatigue) as it may inflate depression scores caused by 
symptoms inherent in the illness rather than depression (Moore, Moore & Shaw, 1998). 
Alexander et al. (2012) reported that, in individuals with multiple comorbid chronic 
conditions, greater perceived quality of relationship with clinicians was associated with higher 
levels of patient activation. Although participants perceived high levels of clinician empathy, 
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our conflicting result may indicate that MS individuals’ activation levels could be less reliant 
on empathy within the patient-clinician relationship given the relatively infrequent contact 
with clinicians compared to some other health conditions. Additional aspects of the 
relationship, such as treatment goal-setting (Alexander et al., 2012) might be important to 




Patient activation was a unique predictor of self-management for MS in the current study. 
This study is the first to establish a relationship between activation and self-management in 
MS. Nevertheless, this finding is in line with previous research that has shown a significant 
positive relationship between patient activation and self-management behaviours in other 
LTCs such as exercising, medication adherence, managing stress and using self-management 
services (e.g. emotional support groups and health education classes) (Mosen et al., 2007). 
Our findings indicate that viewing oneself as having the knowledge, skills and confidence to 
take an active role in health management may promote the implementation of self-
management behaviours when faced with MS.  
 
Several studies have used the PAM-13 for predicting self-management behaviours (Greene et 
al., 2015; Marshall et al., 2013; Mosen et al., 2007) and, although the measure does not focus 
on specific behaviours, it may be that the PAM-13 is likely to predict variance in self-
management as several items of the PAM-13 capture confidence in engaging with self-
management behaviours. Whilst there may be some potential questions around conceptual 
overlap with PAM-13 and self-management measures, this study found that patient activation 
only demonstrated a medium correlation (.43) with MS self-management. Goodworth et al. 
(2016) reported a slightly larger association (.50) between patient activation and MS self-
efficacy, possibly, because patient activation is more concerned with feelings of confidence 
and beliefs about one’s ability to manage their own health rather than implementing specific 
self-management behaviours. Illness-specific self-management measures may capture 
elements of the patient activation construct; however, the strength of the inter-correlation 
in this study appears to indicate that self-management and patient activation are related but 
separate constructs. 
 
We further explored this issue in the current study by examining the strongest correlations 
between items on the PAM-13 and MSSM-R to ascertain which items had the most potential 
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conceptual overlap. The three highest correlated items emerged with an r value ≥.40 (r=.40; 
r=.47; r=.47). These three items were then removed from the MSSM-R and a ‘new’ self-
management measure variable was created for the purposes of data analysis. Cronbach’s 
alpha for the ‘new’ measure was .71. Hierarchical regression analyses were re-run with the 
‘new’ self-management measure as the outcome variable. Depression, clinician empathy and 
valued living were entered as predictors in step 1; and patient activation was entered as a 
predictor in step 2. After entry, and consistent with the final model presented in our results 
(see Table 5), patient activation remained statistically significant with higher levels of patient 
activation associated with greater MS self-management. 
 
While there are related elements between patient activation and self-management, our view 
is that the PAM-13 captures additional information. As well as assessing knowledge, skills and 
confidence for self-management, it also appears to capture information about an individual’s 
self-efficacy, resilience and locus of control regarding self-management tasks. On the other 
hand, patient activation as a conceptually distinct construct seems individually incapable of 
measuring specific clinically relevant information provided by multi-dimensional self-
management tools. The issue of conceptual versus measurement overlap between patient 
activation and self-management remains largely unexplored but invites interesting reflections 
around the notion that measurement science and theory building coexist. Kelle (2015) has 
suggested that instruments designed to capture latent constructs, like patient activation and 
self-management, must account for and acknowledge the role of previous theoretical findings; 
similarly, theoretical knowledge can only be applied and tested with the use of valid and 
reliable measures. 
 
Interestingly, perceived clinician empathy made a greater contribution to self-management 
than patient activation. MS patients may rely on the therapeutic relationship with their 
clinicians to ‘check in’, which may reinforce positive self-management behaviours (Alexander, 
Hearld & Mittler, 2014). Our finding perhaps indicates that a therapeutic alliance with 
healthcare providers has a buffering effect when patients are less activated. Further 
exploration of sub-components of the patient-clinician relationship to examine which aspects 
predict greater self-management in MS may be warranted.  
 
Depression was not a significant predictor of self-management in our study, which seems 
unexpected given that previous research has shown that depressed individuals are less likely 
to attend and engage with self-management programmes (Cassidy, Turnball, Gardani & 
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Kirkwood, 2014; Hadgkiss et al., 2015). Valued living was not a significant predictor of self-
management for MS when patient activation was added to the regression model. Thus, may 
suggest that valued living and patient activation may have some shared variance in relation to 
predicting self-management for MS. 
 
4.2 Methodological considerations  
 
This study was the first to explore the relative role of depression, valued living and clinician 
empathy as predictors of patient activation, and to establish an association between patient 
activation and self-management for MS. The use of the PAM-13, which is currently the only 
measure to capture this construct, allowed for the possibility of assessing patient engagement 
from a transdiagnostic perspective that is comparable across different health conditions. 
Goodworth et al. (2016) attempted to ascertain some of the modifiable variables associated 
with patient activation in MS and suggested that addressing depression may be a key 
treatment target. The present study investigated two unexplored variables to identify further 
areas of intervention for people at risk of lower levels of activation and poorer self-
management. The study was sufficiently powered and validated measures with robust 
psychometric properties were utilised, most of which had been previously demonstrated in 
an MS population. The sample was recruited from one NHS site in Scotland and while this 
might introduce a degree of bias, the high response rate (77%) and participant demographic 
characteristics suggest the sample is broadly representative of a UK MS population. The 
method for data collection may have created further bias whereby individuals with greater 
functional disability were unable to participate, however, the high response rate in this study 
is encouraging.  
 
It would be valuable to integrate self-report measures with direct measures of MS self-
management such as medication adherence and lifestyle behaviour. This endeavour may 
require creative methods of measurement but would be an important addition to enhance 
validity of future studies. The cross-sectional design prevents causal inference; therefore, 
future research could entail experimental studies explicitly manipulating and testing causal 
links between variables. Finally, the present study also highlights a need for longitudinal 
research to increase confidence in findings and explore new ideas. One potentially interesting 
and valuable area of future research would be longitudinal studies that follow patient 
activation in the context of disease progression (i.e. transition from relapsing-remitting to 
progressive MS diagnosis).  
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4.3 Clinical implications 
 
Whilst causality cannot be inferred from these results, our findings have important 
implications for clinicians working with individuals with MS. Clinicians largely depend on 
patients’ own management of seeking help when required, making lifestyle alterations and 
adhering to therapeutic recommendations. Patients with low activation are less likely to play 
an active role in staying healthy, present to health services when required and adhere to 
treatment recommendations (Hibbard & Gilburt, 2014). Our finding that perceived clinician 
empathy might predict better self-management of MS recognises the key role of clinicians’ in 
supporting and reinforcing adaptive behaviours. Clinicians could assess constructs like valued 
living and perceived empathy and target interventions to promote these processes in an effort 
to improve activation and self-management in people with MS. Clinical consultations or 
interventions to activate patients might be more successful when linked to the patient’s values, 
particularly those around physical self-care, self-direction and social relationships. Measures 
that assess value-consistent behaviour in various life domains (e.g. physical self-care, 
recreation), may be clinically useful as part of consultations to identify individuals who might 
be at risk for lower activation and are in need of support.  
 
There is growing evidence that value-consistent behaviour can be enhanced with 
interventions like Acceptance and Commitment Therapy which aim to improve quality of life 
and functioning by cultivating patients’ acceptance of difficult, and sometimes unchangeable, 
circumstances and commitments to personally held values (Wersebe et al., 2017). ACT has 
been shown to increase valued living and reduce psychological distress in MS (Gillanders & 
Gillanders, 2014; Nordin & Rorsman, 2012), but it may also promote meaningful change with 
regard to activating patients to engage in self-management activities. In accordance with 
government strategies (NHS England, 2016) for the management of long-term conditions that 
call for “healthcare professionals to abandon traditional ways of thinking” (Coulter, Roberts 
& Dixon, 2013, p. 1), it could be argued that increased knowledge about the role of other 
ACT-related constructs in relation to activation for self-management may provide an 




The current study expands the existing literature by demonstrating that valued living is 
associated with patient activation when gender, age, education and symptom severity are 
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controlled for in an MS population. It further established that patient activation and perceived 
clinician empathy are associated with MS self-management when depression and valued living 
are controlled for. The findings suggest that self-management interventions, which integrate 
components to enhance valued living and the patient-clinician relationship, may be effective 
for addressing low levels of patient activation and enhancing self-management behaviours in 
some people living with MS. 
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the Submission Checklist to help your prepare your paper.
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• Contributions must be typed in double spacing with wide margins. All sheets must be 
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affiliations, as well as the corresponding author's contact details. You may like to 
use this template. When entering the author names into Editorial Manager, the corresponding 
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• Conflict of interest statement: We are now including a brief conflict of interest statement at 
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• Tables should be typed in double spacing, each on a separate page with a self-explanatory 
title. Tables should be comprehensible without reference to the text. They should be placed at 
the end of the manuscript but they must be mentioned in the text. 
 
• Figures can be included at the end of the document or attached as separate files, carefully 
labelled in initial capital/lower case lettering with symbols in a form consistent with text use. 
Unnecessary background patterns, lines and shading should be avoided. Captions should be 
listed on a separate sheet. The resolution of digital images must be at least 300 dpi. All figures 
must be mentioned in the text. 
 
• For reference citations, please use APA style. Particular care should be taken to ensure that 
references are accurate and complete. Give all journal titles in full and provide doi numbers 
where possible for journal articles. For example:  
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• SI units must be used for all measurements, rounded off to practical values if appropriate, 
with the imperial equivalent in parentheses. 
 
• In normal circumstances, effect size should be incorporated. 
 
• Authors are requested to avoid the use of sexist language. 
 
• Authors are responsible for acquiring written permission to publish lengthy quotations, 
illustrations, etc. for which they do not own copyright. For guidelines on editorial style, please 
consult the APA Publication Manual published by the American Psychological Association. 
 
• Manuscripts describing clinical trials are encouraged to submit in accordance with 
the CONSORT statement on reporting randomised controlled trials. 
 
• Manuscripts reporting systematic reviews and meta-analyses are encouraged to submit in 
accordance with the PRISMA statement. 
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• Manuscripts reporting interventions are encouraged to describe them in accordance with 
the TIDieR checklist. 
 
6. Supporting information 
 
Supporting Information can be a useful way for an author to include important but ancillary 
information with the online version of an article. Examples of Supporting Information 
include appendices, additional tables, data sets, figures, movie files, audio clips, and other 
related nonessential multimedia files. Supporting Information should be cited within the 
article text, and a descriptive legend should be included. Please indicate clearly on 
submission which material is for online only publication. It is published as supplied by the 
author, and a proof is not made available prior to publication; for these reasons, authors 
should provide any Supporting Information in the desired final format. 
 
For further information on recommended file types and requirements for submission, please 




OnlineOpen is available to authors of primary research articles who wish to make their article 
available to non-subscribers on publication, or whose funding agency requires grantees to 
archive the final version of their article. With OnlineOpen, the author, the author's funding 
agency, or the author's institution pays a fee to ensure that the article is made available to non-
subscribers upon publication via Wiley Online Library, as well as deposited in the funding 
agency's preferred archive. A full list of terms and conditions is available on Wiley Online 
Library. 
 
Any authors wishing to send their paper OnlineOpen will be required to complete the payment 
form. 
 
Prior to acceptance there is no requirement to inform an Editorial Office that you intend to 
publish your paper OnlineOpen if you do not wish to. All OnlineOpen articles are treated in 
the same way as any other article. They go through the journal's standard peer-review process 
and will be accepted or rejected based on their own merit. 
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8. Author Services 
 
Author Services enables authors to track their article – once it has been accepted – through the 
production process to publication online and in print. Authors can check the status of their 
articles online and choose to receive automated e-mails at key stages of production. The author 
will receive an e-mail with a unique link that enables them to register and have their article 
automatically added to the system. You can then access Kudos through Author Services, 
which will help you to increase the impact of your research. Visit Author Services for more 
details on online production tracking and for a wealth of resources including FAQs and tips 
on article preparation, submission and more. 
 
9. Copyright and licences 
 
If your paper is accepted, the author identified as the formal corresponding author for the paper 
will receive an email prompting them to login into Author Services, where via the Wiley 
Author Licensing Service (WALS) they will be able to complete the licence agreement on 
behalf of all authors on the paper. 
 
For authors signing the copyright transfer agreement 
 
If the OnlineOpen option is not selected the corresponding author will be presented with the 
copyright transfer agreement (CTA) to sign. The terms and conditions of the CTA can be 
previewed in the samples associated with the Copyright FAQs . 
 
For authors choosing OnlineOpen 
 
If the OnlineOpen option is selected the corresponding author will have a choice of the 
following Creative Commons Licence Open Access Agreements (OAA): 
 
- Creative Commons Attribution Non-Commercial Licence (CC-BY-NC) 
- Creative Commons Attribution Non-Commercial -NoDerivs Licence (CC-BY-NC-ND) 
 
To preview the terms and conditions of these open access agreements please visit 
the Copyright FAQs and you may also like to visit the Wiley Open Access Copyright and 
Licence page. 
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If you select the OnlineOpen option and your research is funded by The Wellcome Trust and 
members of the Research Councils UK (RCUK) or the Austrian Science Fund (FWF) you will 
be given the opportunity to publish your article under a CC-BY licence supporting you in 
complying with your Funder requirements. For more information on this policy and the 
Journal’s compliant self-archiving policy please visit our Funder Policy page. 
 
10. Colour illustrations 
 
Colour illustrations can be accepted for publication online. These would be reproduced in 
greyscale in the print version. If authors would like these figures to be reproduced in colour in 
print at their expense they should request this by completing a Colour Work Agreement form 
upon acceptance of the paper. 
 
11. Pre-submission English-language editing 
 
Authors for whom English is a second language may choose to have their manuscript 
professionally edited before submission to improve the English. A list of independent suppliers 
of editing services can be found in Author Services. All services are paid for and arranged by 
the author, and use of one of these services does not guarantee acceptance or preference for 
publication. 
 
12. The Later Stages 
 
The corresponding author will receive an email alert containing a link to a web site. The proof 
can be downloaded as a PDF (portable document format) file from this site. Acrobat Reader 
will be required in order to read this file. This software can be downloaded (free of charge) 
from Adobe's web site. This will enable the file to be opened, read on screen and annotated 
direct in the PDF. Corrections can also be supplied by hard copy if preferred. Further 
instructions will be sent with the proof. Excessive changes made by the author in the proofs, 
excluding typesetting errors, will be charged separately. 
 
13. Early View 
 
Page 107 of 147 
 
British Journal of Health Psychology is covered by the Early View service on Wiley Online 
Library. Early View articles are complete full-text articles published online in advance of their 
publication in a printed issue. Articles are therefore available as soon as they are ready, rather 
than having to wait for the next scheduled print issue. Early View articles are complete and 
final. They have been fully reviewed, revised and edited for publication, and the authors’ final 
corrections have been incorporated. Because they are in final form, no changes can be made 
after online publication. The nature of Early View articles means that they do not yet have 
volume, issue or page numbers, so they cannot be cited in the traditional way. They are cited 
using their Digital Object Identifier (DOI) with no volume and issue or pagination information. 
E.g. Jones, A.B. (2010). Human rights Issues. Journal of Human Rights. Advance online 
publication. doi:10.1111/j.1467-9299.2010.00300.x 
 
Further information about the process of peer review and production can be found in this 
document. What happens to my paper? Appeals are handled according to the procedure 
recommended by COPE.
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Appendix B: Taxonomy of Self-Management Components for Coding Studies 
 
TAXONOMY ELABORATION EXAMPLES FROM STUDIES INCLUDED IN THIS REVIEW (DELIVERED DIRECTLY TO PATIENTS) 
1. EDUCATION ABOUT 
CONDITION AND 
MANAGEMENT 
-- • Explanation of cardiovascular risk and dysglacaemia; symptoms, physiology, causes and treatment. 
• 3-week patient education programme, covering living with diabetes, epidemiology, basic 
knowledge, complications, improving metabolic control, measuring blood glucose, diet and 
physical activity (diabetes) 
2. INFORMATION ABOUT 
AVAILABLE RESOURCES 
Including:  
• financial benefits  
• social support  
• charitable organisations 
• Advice on accessing community resources (chronic poly-arthritis) 
3. PROVISION OF/AGREEMENT 
ON SPECIFIC ACTION PLANS 
AND/OR RESCUE MEDICATION 
Definition: 
• a personalised action plan 
should be tailored to the 
person, enabling people to 
recognise when symptoms are 
worse and setting out actions 
to be taken when control 
deteriorates 
• Use of behavioural change problem-solving care plan or contract where patient sets up a plan for a 
difficult time, discuss and adjust plan with HP as appropriate (chronic heart failure) 
4. REGULAR CLINICAL REVIEW -- • External regular review (chronic poly-arthritis) 
5. MONITORING OF 
CONDITION WITH FEEDBACK 
TO THE PATIENT  
Including: 
• feedback from clinician 
• feedback from technology 
• self-evaluation 
• Weekly testing and review of A1C level and opportunity to discuss A1C value with community 
health reps following education classes, who gave personalised feedback / recommendations to 
patients (diabetes) 
• Remote monitoring system to provide timely alerts and feedback from health professional in 
response to worrisome responses to a question or vital signs being outside pre-set limits (chronic 
heart failure) 
6. PRACTICAL SUPPORT WITH 
ADHERENCE (MEDICATION OR 
BEHAVIOURAL)  
Including:  
• medicine reviews 
• dosette boxes 
• prompts 
• reminder checklists  
• Biweekly telephone calls by nurse to review patient’s blood pressure log and medication 
adherence (hypertension) 
• Weekly reminder emails to patients to facilitate adherence to complete online self-management 
modules for 6 weeks (osteoarthritis)  
• ‘Buddy’ system to increase compliance with exercise participation (diabetes) 
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TAXONOMY ELABORATION EXAMPLES FROM STUDIES INCLUDED IN THIS REVIEW (DELIVERED DIRECTLY TO PATIENTS) 
7. PROVISION OF EQUIPMENT -- • Remote monitoring device provided to record weight, heart rate and blood pressure daily (chronic 
heart failure)  
• All intervention group participants were provided with a pedometer free of charge to record levels 
of physical activity daily (diabetes) 
8. SAFETY NETTING Including:  
• specialist telephone advice 
• out of hours advice 
• Availability of electronic messaging with healthcare professional in addition to access to patient 
portal. 
9. TRAINING/REHEARSAL TO 
COMMUNICATE WITH HEALTH 
PROFESSIONALS  
-- • Patients taught skills via group-based activities around ‘Making the most of consultations with 
health professionals’ and ‘Preparing for clinical consultations’ (COPD) 
• ‘Talking with healthcare providers’ covered as part of self-management program (sickle cell 
disease)  
10. TRAINING/REHEARSAL 
FOR ACTIVITIES OF DAILY 
LIVING 




-- • Training in measuring blood glucose (diabetes) 











• cognitive restructuring 
• Personal goals aimed at improving self-management of disease (sickle cell disease) 
• Patients taught techniques to deal with frustration, fatigue, pain and isolation (mixed health 
conditions) 
• Mindfulness practice, relaxation training and handling unhelpful emotions (COPD) 
13. SOCIAL SUPPORT Including: 
• Befriending 
• peer support 
• peer mentoring 
• group socialising 
• Encouraging participants to interact and to assess their own and their peers’ progress towards 
managing their condition by sharing ideas, advice and support with each other  
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TAXONOMY ELABORATION EXAMPLES FROM STUDIES INCLUDED IN THIS REVIEW (DELIVERED DIRECTLY TO PATIENTS) 




• Physical activity 
• smoking cessation 
• Participant walking groups organised and assisted by health care providers as part of intervention 
• Nutritionist providing information to enhance physical activity and dietary intake. 
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Appendix C: Quality Criteria and Assessment of Bias Tool 







QC1. Does the study design provide sufficient evidence that Patient Activation 
outcomes are due to the intervention? 
Well-covered Randomised controlled trial (RCT) 
Adequately 
addressed 
Non-randomised controlled trial / multiple baseline 
Poorly 
addressed 
Repeated measures design / uncontrolled trial 
Not reported / 
Not applicable  
Single case experimental design / case study with pre-post quantified 
data 
 
QC2.  Are the recruitment method and inclusion/ exclusion criteria appropriate to 
ensure a representative sample that can be generalised? 
Well-covered Representative recruitment procedure (e.g. random sampling) applied to 
reduce selection bias and appropriate sample eligibility criteria are 
applied to address the review aims (e.g. a homogenous sample of 
individuals with the same, defined long-term health condition requiring 
clear and specific self-management behaviours). 
Adequately 
addressed 
Convenience recruitment procedure applied, but appropriate attempts 
have been made to address sample representativeness or participants’ 
inclusion criteria are only adequately appropriate to address the review 
aims (e.g. a heterogeneous sample of individuals with mixed long-term 
health conditions requiring a variety of self-management behaviours). 
Poorly 
addressed 
Convenience recruitment procedure without sufficient attempts to reduce 
bias in sample selection or participants inappropriate to address the 
review aims (e.g., heterogeneous sample of individuals with defined but 
mixed long-term conditions not restricted to physical health requiring a 
variety self-management behaviours). 
Not reported / 
Not applicable  
 
Recruitment method poorly described & unclear eligibility criteria or 
participant characteristics (e.g., a sample of individuals with long-term 
conditions which are not specified). 
 
QC3.  Is sample size (power) sufficient for analysis relating to pre and post Patient 
Activation outcome measure? 
Well-covered Number of participants who completed both pre-and post-measures in 
the intervention group is sufficient to achieve power of at least 0.8, where 
a medium effect size is anticipated, and alpha is 0.5. 
Adequately 
addressed 
Number of participants who completed both pre-and post-measures in 
the intervention group is sufficient to achieve power of at least 0.7, where 
a medium effect size is anticipated, and alpha is 0.5. 
Poorly 
addressed 
Number of participants who completed pre-and post-measures in the 
intervention group is sufficient to achieve power of less than 0.7, where a 
medium effect size is anticipated, and alpha is 0.5. 
Page 112 of 147 
 
Not reported / 
Not applicable 
Sample size not reported / known 
QC4.  Is the allocation appropriate to address allocation bias? 
 
Well-covered  Appropriate process of allocation to treatment groups is applied to 
address bias and investigator(s) and / or participants are blinded (e.g. 
random allocation method used). 
Adequately 
addressed 
Only adequate process of allocation to groups is used to address bias 
(e.g. poor randomisation method used or investigator(s) and / or 
participants are not blinded). 
Poorly 
addressed 
Control group is not randomised. 
Not reported / 
Not applicable  
No control group used. 
QC5.  Are groups comparable at baseline on key variables? * 
Well-covered The treatment and control groups are comparable at baseline or 




The treatment and control groups only adequately comparable at 




The treatment and control groups are not comparable at baseline or no 
attempt has been made to address the differences or control group is 
used. 
Not reported / 
Not applicable 
No control group is used.  
*Note Key baseline variables include: Patient Activation; severity of health 
condition; age; gender; and education, where applicable. 
QC6.  The Patient Activation Measure is appropriately administered and validated 
for use in sample population(s) or similar? 
Well-covered  Good reliability and / or validity properties are reported (≥0.8) in the study 
population(s) or similar population(s), with good reason to believe they 
would apply to the current study population (e.g. where the level and type 
of self-management required is similar between long-term conditions). 
Adequately 
addressed 
Adequate reliability and / or validity properties reported (≥0.5 and <0.8) in 
the study population(s) or similar population(s), with good reason to 
believe they would apply to the current study population (e.g. where the 




Poor psychometric properties reported (<0.5) in the study population(s) 
or similar population(s). 
Not reported / 
Not applicable 
Psychometric properties are not known in the study population(s). 
QC7.  Follow-up PAM is administered to evaluate if effects are maintained long-
term?  




Short-term (≥3 and <6 months) post-intervention follow-up scores 
available for PAM measure. 




Post-intervention follow-up of <3 months duration. 
Not reported / 
Not applicable 
No post-intervention follow-up data available for PAM. 
QC8.  The self-management intervention is suitable for increasing Patient Activation 
in the context of long-term conditions? * 
Well-covered  A sufficiently detailed self-management intervention is used, and this 
seems appropriate to increase Patient Activation (number of sessions, 
content* and level of input). 
Adequately 
addressed 
An adequately detailed self-management intervention is used, or this 
seems only partially appropriate to improve Patient Activation (number of 
sessions, content* and level of input). 
Poorly 
addressed 
The self-management intervention is not sufficient to ensure validity or is 
not adequate to increase Patient Activation (number of sessions, 
content* and level of input). 
Not reported / 
Not applicable 
Intervention is not described and details not available. 
*Note A sufficient self-management intervention should include the provision of 
education plus at least two additional components based on the 
taxonomy of self-management support components by Taylor et al. 
(2014). Other consideration of suitability includes whether the 
intervention is standardised or is locally developed. 
QC9. Is the delivery of the intervention conducted and assessed appropriately? 
Well-covered  The treatment is conducted by health professionals and / or peer 
facilitators who have received suitable training in the intervention. 
Accurate and consistent application of the intervention is also suitably 




The treatment is peer-led or conducted by health professionals who have 
received adequate training in the intervention. Accurate and consistent 
application of the intervention may or may NOT be adequately measured 
but biased (e.g. self- or participant-rated).  
Poorly 
addressed 
The treatment is not conducted by suitably trained individuals and no 
appropriate measurement of accurate and consistent application of the 
intervention is used. 
Not reported / 
Not applicable 
No information about the facilitators’ background / training or procedure 
to access fidelity available. 
QC10. Attrition at post-intervention* is low and / or comparable to control group?  
Well-covered Attrition from the study is low (≤30%) and, if applicable, approximately 
equal across treatment and control group (e.g. ≤10%). 
Adequately 
addressed 
Attrition from the study is moderate (>30-49%) or, if applicable, less than 
30% but with moderately unequal dropout rates across treatment and 
control group (e.g. >11-19%). 
Poorly 
addressed 
Attrition from the study is poor (≥50%) and, if applicable, with 
substantially unequal dropout rates across treatment and control group 
(e.g. ≥20%). 
Not reported / 
Not applicable 
Attrition rates at post intervention are not reported or considered. 
*Note Attrition refers to non-completion of the Patient Activation Measure at 
post-intervention. 
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QC11. Attrition at follow-up* is low and / or comparable to control group? 
Well-covered Attrition from the study is low (≤30%) and, if applicable, approximately 
equal across treatment and control group (e.g. ≤10%). 
Adequately 
addressed 
Attrition from the study is moderate (>30-49%) or, if applicable, less than 
30% but with moderately unequal dropout rates across treatment and 
control group (e.g. >11-19%). 
Poorly 
addressed 
Attrition from the study is poor (≥50%) and, if applicable, with 
substantially unequal dropout rates across treatment and control group 
(e.g. ≥20%). 
Not reported / 
Not applicable 
Attrition rates at follow-up are not reported or considered. 
*Note If applicable, attrition refers to non-completion of the Patient Activation 
Measure at the longest follow-up period within the study. 
 
QC12. Analysis is appropriate for the review aims, measure and study design (e.g. 
adjusted for potential confounders*) and outcomes are appropriately reported? 
Well-covered An appropriate statistical analysis is conducted (excl. missing data 
analysis) and the outcomes are appropriately reported, AND potential 
confounders are clearly specified and controlled for, where applicable.  
Adequately 
addressed 
An adequately appropriate statistical analysis is conducted (excl. missing 
data analysis) and the outcomes are only adequately reported. Baseline 
differences between groups are specified and controlled for. 
Poorly 
addressed 
Inappropriate or poorly conducted statistical analysis is used or the 
outcomes are poorly reported. Potential confounders are not considered 
or controlled for.  
Not reported / 
Not applicable 
Statistical analysis not carried out or reported OR potential confounders 
are not considered. 
*Note Potential confounders related to the Patient Activation construct include 
baseline differences in age, education and PAM scores. 
QC13. Is the method to address missing data suitable? 
Well-covered No missing data or intention to treat analysis / appropriate alternative 
(e.g. maximum likelihood, if missing data are likely to be random) is used.  
Adequately 
addressed 




Missing data are poorly addressed 
Not reported / 
Not applicable 
No missing data analyses are reported or there is a lack of clarity 
regarding the method used. 
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South West - Exeter Research Ethics Committee  
Whitefriars  
Level 3  
Block B  
Lewins Mead  
Bristol  
BS1 2NT  
  
Telephone: 0207 104 8043  
  
 06 January 2017  
  
Ms Laura Alexander  
Department of Clinical Neurosciences   
Western General Hospital  
Crewe Road, Edinburgh  
EH4 2XU  
  
  
Dear Ms Alexander  
  
Study title:  Patient Activation in Multiple Sclerosis: the role of depression, 
value-based living and perceived clinician empathy.  
REC reference:  16/SW/0330  
IRAS project ID:  
  
213383  
Thank you for your letter of the 21st December 2016, responding to the Proportionate 
Review Sub-Committee’s request for changes to the documentation for the above study.  
  
The revised documentation has been reviewed and approved by the sub-committee.  
  
We plan to publish your research summary wording for the above study on the HRA 
website, together with your contact details. Publication will be no earlier than three months 
from the date of this favourable opinion letter. The expectation is that this information will 
be published for all studies that receive an ethical opinion but should you wish to provide a 
substitute contact point, wish to make a request to defer, or require further information, 
please contact please contact hra.studyregistration@nhs.net outlining the reasons for your 
request.  
 
Under very limited circumstances (e.g. for student research which has received an 
unfavourable opinion), it may be possible to grant an exemption to the publication of the 
study.  
 
Confirmation of ethical opinion  
On behalf of the Committee, I am pleased to confirm a favourable ethical opinion for the 
above research on the basis described in the application form, protocol and supporting 
documentation as revised.  
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Conditions of the favourable opinion  
  
The REC favourable opinion is subject to the following conditions being met prior to the 
start of the study.  
  
Management permission must be obtained from each host organisation prior to the start of 
the study at the site concerned.  
  
Management permission should be sought from all NHS organisations involved in the 
study in accordance with NHS research governance arrangements. Each NHS 
organisation must confirm through the signing of agreements and/or other documents that 
it has given permission for the research to proceed (except where explicitly specified 
otherwise).   
Guidance on applying for HRA Approval (England)/ NHS permission for research is 
available in the Integrated Research Application System, www.hra.nhs.uk or at 
http://www.rdforum.nhs.uk.   
  
Where a NHS organisation’s role in the study is limited to identifying and referring potential 
participants to research sites (“participant identification centre”), guidance should be 
sought from the R&D office on the information it requires to give permission for this 
activity.  
  
For non-NHS sites, site management permission should be obtained in accordance with 
the procedures of the relevant host organisation.  
  
Sponsors are not required to notify the Committee of management permissions from host 
organisations.   
  
Registration of Clinical Trials  
  
All clinical trials (defined as the first four categories on the IRAS filter page) must be 
registered on a publically accessible database. This should be before the first participant is 
recruited but no later than 6 weeks after recruitment of the first participant.  
There is no requirement to separately notify the REC but you should do so at the earliest 
opportunity e.g. when submitting an amendment.  We will audit the registration details as 
part of the annual progress reporting process.  
   
To ensure transparency in research, we strongly recommend that all research is registered 
but for non-clinical trials this is not currently mandatory.  
   
If a sponsor wishes to request a deferral for study registration within the required 
timeframe, they should contact hra.studyregistration@nhs.net. The expectation is that all 
clinical trials will be registered, however, in exceptional circumstances non registration 
may be permissible with prior agreement from the HRA. Guidance on where to register is 
provided on the HRA website.  
  
It is the responsibility of the sponsor to ensure that all the conditions are complied 
with before the start of the study or its initiation at a particular site (as applicable).  
  
Ethical review of research sites  
  
The favourable opinion applies to all NHS sites taking part in the study, subject to 
management permission being obtained from the NHS/HSC R&D office prior to the start of 
the study (see “Conditions of the favourable opinion” above).  
  
Approved documents  
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The documents reviewed and approved by the Committee are:  
  
Document    Version    Date    
Covering letter on headed paper 
[Response Letter to REC]   
version 1   10 December 2016  
Covering letter on headed paper [REC 
response letter 2]   
N/A   21 December 2016  
GP/consultant information sheets or 
letters [GP Letter informing of 
participation]   
version 3   20 December 2016  
GP/consultant information sheets or 
letters [MS Clinician Information Letter]   
version 2   20 December 2016  
IRAS Checklist XML 
[Checklist_09112016]   
   09 November 2016  
IRAS Checklist XML 
[Checklist_16122016]   
   16 December 2016  
IRAS Checklist XML 
[Checklist_21122016]   
   21 December 2016  
Letters of invitation to participant 
[Participant cover / invitation letter]  
version 1   07 November 2016  
Letters of invitation to participant 
[Participant Cover Letter]   
version 2   20 December 2016  
Non-validated questionnaire 
[Demographic Questionnaire]   
version 1   14 October 2016   
Non-validated questionnaire 
[Demographic Questionnaire]   
version 2   20 December 2016  
Other [Guidance notes for completing 
questionnaires]   
version 1   14 October 2016   
Other [Guidance sheet for Participants 
Completing Questionnaires]   
version 2   20 December 2016  
Other [Participant Thank You Letter]   version 2   20 December 2016  
Other [Permission to Contact Form]   version 1   01 December 2016  
Participant consent form [Participant 
Consent Form]   
version 3   20 December 2016  
Participant information sheet (PIS) 
[Participant Information Sheet]   
version 3   20 December 2016  
REC Application Form 
[REC_Form_09112016]   
   09 November 2016  
Research protocol or project proposal 
[Study Protocol]   
version 2   20 December 2016  
Summary CV for Chief Investigator 
(CI) [CV for CI]   
Version 1   11 October 2016   
Summary CV for supervisor (student 
research) [CV for supervisor]   
version 1   08 November 2016  
Validated questionnaire [Patient 
Activation Measure]   
version 2   20 December 2016  
Validated questionnaire [Multiple 
Sclerosis Impact Scale]   
version 2   20 December 2016  
Validated questionnaire [Engaged 
Living Scale]   
version 2   20 December 2016  
Validated questionnaire [CARE 
Measure]   
version 2   20 December 2016  
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Validated questionnaire [Hospital 
Anxiety and Depression Scale]   
Version 2   20 December 2016  
Validated questionnaire [Multiple 
Sclerosis Self-Management Scale]  
version 2   20 December 2016  
  
Statement of compliance  
  
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating Procedures 
for Research Ethics Committees in the UK.  
  
After ethical review  
  
Reporting requirements  
  
The attached document “After ethical review – guidance for researchers” gives detailed 
guidance on reporting requirements for studies with a favourable opinion, including:  
  
• Notifying substantial amendments  
• Adding new sites and investigators  
• Notification of serious breaches of the protocol  
• Progress and safety reports  
• Notifying the end of the study  
  
The HRA website also provides guidance on these topics, which is updated in the light of 




You are invited to give your view of the service that you have received from the Research 
Ethics Service and the application procedure.  If you wish to make your views known 
please use the feedback form available on the HRA website:  
http://www.hra.nhs.uk/about-the-hra/governance/quality-assurance   
  
We are pleased to welcome researchers and R & D staff at our RES Committee members’ 
training days – see details at http://www.hra.nhs.uk/hra-training/   
  








Pp   
 
Mrs Joan Ramsay Vice - Chair  
  
Email: nrescommittee.southwest-exeter@nhs.net  
  
Enclosures:     “After ethical review – guidance for researchers”   
  
Copy to:  Ms Charlotte Smith  
  
Mr Gavin Robertson, NHS Lothian Research & Development Office 
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Appendix E: NHS Lothian Research and Development Approval Letter 
 
University Hospitals Division    
Lothian 
Queen's Medical Research Institute 
47 Little France Crescent, Edinburgh, EH16 4TJ 
FM/CF/approval 
6 January 2017        
 
Research & Development 
Mrs Shuna Colville     Room El .12 
    
University of Edinburgh     Tel: 0131 242 3330 
Anne Rowling Regenerative neurology Clinic  Email:  
Chancellor's Building                  accord@nhslothian.scot.nhs.uk 
49 Little France Crescent    Director: Professor David E Newby 
Edinburgh 
EH16 4SB      
 
Dear Mrs Colville 
Lothian R&D Project No: 2016/0321 REC No: 16/SW/0330 
Title of Research: Patient Activation in Multiple Sclerosis: the role of depression, 
value-based living and perceived clinician empathy. 
Participant Information Sheet: Consent Form: 
Version 3.0, dated 20 December 2016 Version 3.0, 20 December 2016 
Protocol: Version 2.0, dated 20 December 2016 
I am pleased to inform you this letter provides Site Specific approval for NHS Lothian for 
the above study and you may proceed with your research, subject to the conditions 
below. 
Please note that the NHS Lothian R&D Office must be informed of any changes to the 
study such as amendments to the protocol, funding, recruitment, personnel or resource 
input required of NHS Lothian. 
Substantial amendments to the protocol will require approval from the ethics committee 
which approved your study and the MHRA where applicable. 
Please keep this office informed of the following study information: 
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1. Date you are ready to begin recruitment, date of the recruitment of the first 
participant and the quarterly recruitment figures thereafter. 
2. Date the final participant is recruited and the final recruitment figures. 
3. Date your study / trial is completed within NHS Lothian. 
 
I wish you every success with your study. 
Yours sincerely 
 
Ms Fiona McArdle 
Deputy R&D Director 
CC: Mrs Laura Alexander, University of Edinburgh
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Appendix F: Study Protocol 
 





Patient Self-Management in Multiple Sclerosis: the role of depression, value-




Dr Paul Morris 
Dr David Gillespie 
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LIST OF ABBREVIATIONS  
 
ACCORD Academic and Clinical Central Office for Research & Development 
- Joint office for University of Edinburgh and NHS Lothian 
ACT Acceptance and Commitment Therapy 
ARRNC Anne Rowling Regenerative Neurology Clinic 
CARE Measure Consultations and Relational Empathy Measure 
ELS Engaged Living Scale 
HADS Hospital Anxiety and Depression Scale 
ICD-10 International Classification of Diseases - 10 
LTC(s) Long Term Condition(s) 
MS Multiple Sclerosis 
MSIS-29 Multiple Sclerosis Impact Scale - 29 
MSSM-R Multiple Sclerosis Self-Management Scale - Revised 
PA Patient Activation 
PAM Patient Activation Measure 
PwMS Persons with Multiple Sclerosis 
QoL Quality of Life 
VBL Value-Based Living 
 




Multiple Sclerosis (MS) is a complex, unpredictable illness and self-management is a key 
treatment component. Research shows that Patient Activation, the willingness and capacity of 
a person to take on the role of self-managing their health, is a key concept of effective self-
management and health outcomes. However, levels of Patient Activation in those with long-
term conditions can vary. Little research has explored Patient Activation in those affected by 
MS. Exploring levels of Patient Activation and factors that may influence patient self-
management is of value as it can help to identify patient needs in relation to self-management 
early on and may allow for preparatory or additional support to be provided in order to allow 
them to gain benefit.  
 
Reasons that individuals may experience low Patient Activation levels may include; the type 
of MS they have; feeling low in mood; and personal demographic variables like age, gender 
and level of education. Several variables remain underexplored but seem important to Patient 
Activation levels including: the severity of symptoms as experienced by the person (regardless 
of MS type); feeling detached from personal values (often called “value-based living”); and the 
quality of relationship quality the individual experiences with their healthcare professional 
(often called “clinician empathy”).  The main research question is: do depression, value-based 
living and clinician empathy explain the variance in Patient Activation levels, over and above 
patient demographic variables and MS symptom severity?  
 
The design of the study means that participants will answer a set of questionnaires once only. 
The study will run for 10 months and recruit those attending the Anne Rowling Regenerative 
Neurology Clinic with a diagnosis of relapsing-remitting or progressive types of MS. Individuals 
will be informed about the study by a researcher and invited to ask questions. They will be 
invited to take the information sheet, consent form and questionnaires home to consider. A 
researcher will contact individuals by phone within one week of being given this information to 
find out if they wish to take part or not. If individuals would like to take part, they will be invited 
to complete and return the questionnaires to the clinic by free-post. The questionnaires will 
ask about factors thought to be important in predicting Patient Activation levels and will take 
around 30 minutes to complete. Participant data collected will be unidentifiable and used in 
statistical analysis to address the research questions. Results of the study will be available by 
Spring/Summer 2018. All participants will be offered a summary of the findings if they are 
interested. This study is an academic, non-profit piece of work being done as part of 
completion of the Doctorate in Clinical Psychology at the University of Edinburgh. 
  
 




Patient Activation and review of the literature 
 
Interest in patients’ self-management of their healthcare is growing as services strive to 
enhance person-centred approaches and improve quality of life (QoL). Patient Activation (PA) 
is a key concept which refers to a person’s willingness and capacity to take on the role of 
managing their own health and health care (Hibbard et al., 2004). The Patient Activation 
Measure (PAM-13; Hibbard et al., 2005) is a measurement scale of Patient Activation asking 
about patient rated knowledge and beliefs about their condition, confidence in treatment 
regimens and self-efficacy (Stepleman et al., 2010). The outcome score places an individual 
at one of four levels of activation, from least activated (1) to most activated (4); the four levels 
of activation are: 
   
• Level 1: Disengaged and overwhelmed  
• Level 2: Becoming aware, but still struggling  
• Level 3: Taking action  
• Level 4: Maintaining behaviours and pushing further 
 
Research highlights that PA is associated with positive changes in health behaviours, 
treatment adherence, health outcomes and cost-efficiency related to illness-management 
(Bodenheimer et al., 2002; Forbat et al., 2009; Hibbard et al., 2007 Hibbard & Greene, 2013).  
 
Individuals with long-term conditions (LTCs) reporting depressive symptomology 
unsurprisingly report lower levels of PA compared with the general population (Hibbard & 
Cunningham, 2008; Lester et al., 2007; Nijman et al., 2014; Rijken et al., 2014). PA is typically 
measured via self-report which may not accord with actual behaviour; although, several 
studies have shown that increases in PA positively correlate with behaviour such as the uptake 
of regular exercise and compliance with medication in various health populations, including 
diabetes and cancer patients (Hibbard et al., 2007; Mosen et al., 2007). These findings provide 
some evidence that PA may have predictive value in determining those likely to engage in 
self-management and, for that reason, collecting additional data on outcomes akin to self-
management and / or quality of life in illness is clinically useful (NHS England, 2016).   
 
To date, two US studies have explored PA in MS (Goodworth et al., 2016; Stepleman et al., 
2010). MS is “a chronic, inflammatory, demyelinating disease of the central nervous system” 
typically diagnosed between 20-40 years of age (Brück & Stadelmann, 2003). Treatment 
involves lifelong management of the disease and symptoms through medication, lifestyle 
changes, physiotherapy and ongoing contact with services. Self-management is therefore 
considered a key component of MS care (Bishop & Frain, 2011). The levels of PA observed in 
people with MS (PwMS) in the US appear to be largely in line with levels of PA in other LTCs 
(e.g. diabetes, cancer) according to Hibbard & Cunningham (2008). One difference was that 
a majority of MS patients scored within a range indicating PA level 3, unlike other chronic 
disease groups with a majority scoring PA level 4 (Stepleman et al., 2010). The authors 
suggest the differences may be attributable to the unpredictability of MS symptom relapses 
and reliance on relationships with healthcare providers which may differ somewhat from other 
LTCs.
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Variables associated with PA in MS   
 
Stepleman, Goodworth and colleagues also found significant negative correlations between 
PA and depression, and significant positive relationships between PA and outcomes of 
psychological wellbeing. Additionally, PA was greater in employed, higher-educated 
participants, similar to findings from papers exploring other LTCs. One surprising outcome was 
that a positive relationship was observed between PA and medication adherence in PwMS but 
the relationship did not reach the levels of significance expected in accordance with the wider 
literature (Bodenheimer et al., 2002; Forbat et al., 2009). Goodworth et al. (2016) have 
published figures suggesting demographic variables, MS-related variables, depression, QoL 
and self-efficacy account for approximately 35 percent of the variance in PA.  
 
Psychological variables associated with PA  
 
The literature surrounding patient self-management and QoL in MS conveys the importance 
of processes aiming to promote positive experiences for patients both inside and outside of 
the clinic. With the increasing popularity of Acceptance and Commitment Therapy (ACT; see 
Hayes et al., 1999 for full details) in the treatment of psychological difficulties in LTCs, interest 
is growing around the role of value-based living (VBL) in psychological outcomes. VBL is 
defined as the extent to which a person is living in accordance with personally-valued aspects 
of life and has received relatively less attention than other constructs related to ACT (Wilson 
et al., 2010). Lundgren et al. (2008) found evidence that VBL mediated seizure activity and 
QoL outcomes in depressed epilepsy patients; while Ciarrochi et al. (2011) has shown that 
VBL was related to improved outcomes on measures of wellbeing and distress in a sample of 
cancer patients. In PwMS, ACT processes have been shown to be stronger mediators of 
psychological outcomes, compared with Cognitive Behaviour Therapy processes, although no 
measure of VBL was included (Ferenbach, 2011). Despite limited studies, the above papers 
provide preliminary evidence that VBL is meaningful in relation to QoL and illness 
management in LTCs. As such, there would appear to be a reasonable basis on which to 
propose VBL may be an important factor in relation to PA in PwMS. 
 
Clinician variables associated with PA 
 
Within the clinic, the patient-clinician relationship may be another key aspect of patients’ 
willingness to participate in autonomous illness management processes, such as presenting 
to healthcare providers for routine or acute care or following treatment plans agreed with 
professionals. There is recognition that an effective, empathic and mutually respectful patient-
clinician relationship is a vital component of establishing patient engagement in healthcare 
and treatment (Rieckmann et al. 2015). Remington et al. (2013) reports that “patients who 
believe they have a high-quality relationship with their clinician are more likely to follow 
treatment recommendations” and that the longevity of the therapeutic relationship is especially 
important in LTCs like MS. Positive patient perceptions of communication and partnerships 
with their clinician is shown to increase patient confidence in healthcare processes and is an 
independent predictor of patient satisfaction with the clinical encounter (Little et al., 2001; von 
Puckler, 2013). It is therefore further hypothesised that the therapeutic relationship between 
MS patients and clinicians would also be a meaningful component to consider in the context 
of PA and self-management behaviours in MS.
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The role of VBL on depression and symptom severity 
 
Relatedly, the wider, more pernicious impact of depression in MS has been observed in poorer 
outcomes relating to physical health and illness management, with lifetime prevalence rates 
of around 50% for depression compared with an estimated 10–15% in the general population 
(Schubert & Foliart, 1993; Siegert & Abernethy, 2005). Evidence suggests that depression has 
a stronger association with patient-reported symptom severity than biological markers of 
disease progression (Chwastiak et al. 2002; Mohr et al., 2001); while DiMatteo et al. (2000) 
has noted that depressed patients are more likely to be non-adherent to treatment 
recommendations than their non-depressed counterparts. The direction of the association 
between depression and severity of symptoms in MS is unclear but is likely to affect 
engagement with positive, meaningful experiences linked with quality of life (Devins & Binik, 
1996). Therefore, there appears to a precedent for examining the role of VBL in depression 
and anxiety, beyond MS symptom severity, in PwMS in order to understand how 
improvements in QoL may be facilitated. 
 
 
1.1 RATIONALE FOR STUDY 
 
PA is particularly relevant in illnesses which are long-term and progressive. Unsurprisingly, 
researchers have tried to understand PA by focusing in on groups of people categorised by 
their particular long-term conditions, including cancer, diabetes and heart disease. To date, 
people affected by MS have received little attention in relation to understanding PA in an 
outpatient sample of PwMS in the UK. 
 
To better understand who is most likely to experience low levels of PA, a number of 
researchers have attempted to identify predictor variables. Current understanding defines 
predictor variables as baseline variables accounting for better or worse outcomes regardless 
of the condition. Whilst there seems to be a large number of variables relating to biological, 
psychological and social factors in predicting levels of PA, a relatively limited number of 
variables have been explored in those with MS including, biological characteristics (e.g. MS 
type), depression and sociodemographic variables (e.g. age, gender and level of education). 
It is proposed that exploring factors that are predictive of PA levels can inform interventions 
which can improve patient self-management and enhance health outcomes and quality of life 
in those with MS. This is important as patient disengagement in illness is costly to both the 
individual and health and public services. Further, if individuals are not receiving the support 
they need to allow them to better self-manage, this can impact on those around them (e.g. 
families, carers and support systems).  
 
There are potentially important variables that have not been examined. This study will focus 
on some of these underexplored variables including, MS symptom severity, value-based living 
and clinician empathy. The predictive value of less explored variables in PA levels over and 
above better known variables will be analysed. 
 
Alongside the research mentioned above, a number of studies have also explored the link 
between PA and the uptake of health-promoting behaviours such as exercise, diet and 
adherence to medication. Few, if any, studies have attempted to link PA levels with the uptake 
of self-management behaviours in PwMS. This is possibly due to a lack of quality methods of 
measuring self-management in MS and the limitations of self-report measures. Nevertheless, 
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it would be a valuable contribution to the limited literature in this area as it is unclear how PA 
levels translate into self-management behaviours specific to MS. This study will also explore 
whether PA levels are associated with patients’ own reports of their engagement in self-
management behaviours associated with MS. 
 
Finally, the wider impact of depression in MS has been shown to relate to poorer outcomes in 
physical health. Research has shown that those affected by MS who are depressed 
experience their symptoms as more severe than those who are not depressed. The reason for 
this is unclear but may be related to experiencing less positive or meaningful experiences in 
life as a result of pain or low mood. Value-based living may be a useful factor to examine in 
relation to mood and anxiety in PwMS, more so than MS symptom severity. Further, VBL may 
act as a moderator variable in the relationship between depression and symptom severity. 
Moderators influence the magnitude of the relationship between two variables and, potentially, 
identify subgroups of people who are more or less likely to experience change. It is, therefore, 
lastly proposed that this study should examine the role of value-based living in depression and 
anxiety and whether value-based living is a moderator variable where there is a relationship 
between depression and severity of MS symptoms. 
 
The proposed hypotheses for this study are: 
 
1. Depression, value-based living and clinician empathy will significantly predict Patient 
Activation levels over and above patient demographic variables and MS symptom 
severity. 
 
2. Higher Patient Activation will be linked to greater uptake of self-management 
behaviours associated with MS. 
 
3. Value-based living and clinician empathy will significantly predict depression and 
anxiety over patient demographic variables and MS symptom severity. 
 
4. Value-based living will moderate the relationship between MS symptom severity and 
depression.
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The primary objective of this study to address the research question: 
 
1. Are depression, value-based living and clinician empathy significantly predictive of 
Patient Activation over and above patient demographic variables and MS symptom 
severity? 
 
2. Is higher Patient Activation linked to greater uptake of self-management behaviours 
associated with MS? 
 
3. Are value-based living and clinician empathy significantly predictive of depression or 
anxiety over and above patient demographic variables and MS symptom severity? 
 





The secondary research objectives of this study are to address the following research 
question: 
 
To explore what levels of Patient Activation are present in an outpatient group of MS patients 
in the UK.
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3. STUDY DESIGN 
 
It is anticipated that this study will run for approximately 10 months in a single-site using a 
cross-sectional sample of patients attending outpatient appointments at the Anne Rowling 
Regenerative Neurology Clinic (ARRNC), Edinburgh Royal Infirmary in NHS Lothian. The data 
will then be examined using multiple hierarchical regressions, correlation and moderation 
analyses to address the research questions. Participants will be asked for some demographic 
information (e.g. age, gender, level of education). The case for collecting sociodemographic 
data in the current study is indicated by previous papers which have established these 
variables account for around 10% of the variance in Patient Activation levels (Goodworth et 
al., 2016). They will also be asked to complete six self-report questionnaires (detailed below) 
measuring: Patient Activation; MS symptom severity; value-based living; depression; the 





1. The Patient Activation Measure – 13 (PAM-13; Hibbard et al., 2005) 
 
The PAM-13 is a 13-item self-report instrument assessing patient skill, knowledge and 
confidence in self-management of their illness. Responses to items such as “I am 
confident that I can follow through on medical treatments I need to do at home” are rated 
from “strongly disagree” to “strongly agree.” Scoring is converted to a scale of 0-100, 
where higher scores illustrate higher levels of Patient Activation. 
 
The scale exhibits good psychometric properties, demonstrating high internal reliability (α 
= .88). Dimensions measuring preventative, consumeristic and disease self-management 
behaviours are strongly associated with activation scores, suggesting strong construct 
validity (Hibbard et al., 2004; Hibbard et al., 2005). A recent study has validated the PAM-
13 in an MS clinic sample (Stepleman et al., 2010). Results suggest the measure 
demonstrates good Rasch person reliability (α = .83), Rasch item reliability (α = .98) and 
comparable internal reliability coefficient for MS populations (α = .88). Strong construct 
validity is reported as with the previous papers, indicating that the scale is a robust and 
suitable measure for use with the MS population. The brevity of the scale also has 
considerable utility in clinical settings.  
 
2. The Multiple Sclerosis Impact Scale (MSIS-29; Hobart et al. 2001)  
 
The MSIS-29 is a self-report measure of MS symptoms with two subscales measuring 
severity of physical and psychological symptoms of the disease. The current study will use 
only the physical subscale of the MSIS-29 as Ferenbach (2011) reports that the 
psychological subscale may demonstrate some theoretical overlap with outcome 
measures of psychological distress. The strong psychometric properties outlined below 
suggest the sole use of the physical subscale in the current study is suitable. Statements 
are rated on a 5-point Likert scale (1 = not at all to 5 = extremely) and pertain to the 
patients’ experience of MS symptoms. The measure was developed from original 129 
items generated from interviews with MS patients and allows for a disease-specific 
measurement of symptom impact as captured by the patients’ perspective; this is not 
offered by other existing scales (Hobart et al., 2001).   
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Hobart et al. (2001) report the MSIS-29 physical subscale displays low floor and ceiling 
effects, good levels of variability and excellent test-retest reliability (r ≥ 0.87) and internal 
consistency (α ≥ 0.91) among a random sample of individuals with relapsing-remitting and 
progressive types of MS. The physical scale is responsive to symptom change (effect size 
g = .82). Hobart et al. (2005) have found the MSIS-29 physical scale to be more sensitive 
to detecting change in physical MS symptoms, compared with various well-established 
scales like the Short-Form Health Survey (SF-36; Ware et al., 1992) and the Expanded 
Disability Status Scale (EDSS; Kurtzke, 1983) over time (see Costelloe et al., 2007 for 
details). 
 
3. The Engaged Living Scale (ELS; Trompetter et al., 2013) 
 
The ELS measures the extent to which a person is engaged in committed action towards 
their values and relates to the valued living aspect of the ACT model. It is a 16-item self-
assessment tool rated on a 5-point Likert scale (1 = not at all to 5 = totally agree) and total 
scores range from 16 to 80, with higher scores demonstrating better engagement in value-
based living. Statements include: “I have values that give my life meaning.” The ELS 
consists of two subscales measuring valued living and life fulfilment. 
 
Trompetter et al. (2013) have evaluated the psychometric properties of the scale in a non-
clinical sample and a clinical sample consisting of chronic pain patients undergoing an 
online ACT intervention. The two subscales and total scale of the ELS demonstrate good 
to excellent internal consistency (Valued Living and Life Fulfilment α = .86; Total Scale α 
= .90). The outcomes on the ELS show positive correlations with related theoretical 
process variables from the ACT model (mindfulness and acceptance) and outcome 
variables in mental health (pain interference in daily life, anxiety, depression and 
psychological wellbeing) (Trompetter et al., 2013). Moreover, this paper found the clinical 
sample to score lower on this scale, suggesting greater discrepancy between values and 
behaviour compared with a normative population. It is felt that the ELS is a suitable 
measure for engagement in value-based living for this project given its brevity and the 
chronic pain sample used in psychometric evaluation of the paper may not be too 
dissimilar to the sample included here. 
 
4. The Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1983) 
 
The HADS is widely used in both clinical and research settings (Herrmann, 1997). It is a 
brief 14-item measuring anxiety and depression. The two subscales can be summed to 
give a total score of psychological distress. In the current study, both subscales will be 
used; depression scores will be included for the main analysis and anxiety scores will be 
included for exploratory analysis. The HADS has good psychometric properties. In a large 
(N = 1792) UK sample (Crawford et al., 2001), the anxiety and depression subscales were 
found to have α values of .82 and .77 respectively, with the total score yielding a value 
of .86. The correlation between the subscales was found to be moderate in magnitude (r 
= .53).   
 
Being a brief measure, the HADS has a low item burden, and is easy to complete. Hence, 
it was considered suitable for use in this study. It has been used previous research with 
PwMS (Spain et al., 2007; Vaughan et al., 2003), including research validating the HADS 
for use with PwMS (Honarmand & Feinstein, 2009). Results of reliability and validity in the 
HADS are shown to be unaffected by cognitive impairment in MS (Gold et al., 2003). 
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5. The Consultation and Relational Empathy Measure (CARE; Mercer et al., 2004) 
 
The CARE Measure is a patient-reported assessment of doctors’ communication and 
empathy in the consultation and takes around 5-10 minutes to complete. The items 
included are theoretically grounded in the concept of empathy in the clinical context (see 
Mercer et al., 2004 for full details). It consists of ten items asking about the ability of the 
doctor to understand and respond to patient concerns (e.g. “How was the doctor at 
showing care and compassion?”). It is rated on a 5-point Likert scale (1 = poor to 5 = 
excellent), with scores ranging from 10 to 50. Higher scores indicate higher perceived 
empathy. The measure demonstrates high internal reliability, with a Cronbach’s alpha 
of .93 and has strong correlations with established measures of empathy such as the 
Reynolds Empathy Scale (r = .84) and the Barrett-Lennard Empathy Subscale (r = .85).  
 
This measure was selected for the current study as it has demonstrated validity in both 
doctor and nursing consultations and has a similarly high internal consistency (α = .97; 
see Bikker et al., 2015). Validation among professionals is considered important in the 
current study given both doctors and nursing staff lead consultations in MS clinics. 
Additionally, a variety of patient demographics and symptom presentations are observed 
in the MS population suggesting the need for a measure which can produce a score that 
is unaffected by patient characteristics. Bikker et al. (2015) has found scores from the 
measure to be unrelated to age, gender, employment, self-reported general health and 
language spoken. Patient reports also suggest that the brevity and relevance of the 
measure are endorsed across various sociodemographic groups (Mercer et al., 2005). 
 
6. The Multiple Sclerosis Self-Management Scale-Revised (MSSM-R; Bishop & Frain, 
2011) 
 
The multidimensional measure comprises of 24 items assessing self-management 
knowledge and behaviors in adults with MS. The scale factors include: 
relationship/communication with health professionals; treatment-related barriers and 
adherence; social supports; knowledge and information about MS; and health 
maintenance behaviours. Ratings are made on a frequency-based scale from 1 (disagree 
completely) to 5 (agree completely), with higher scores indicating better self-management. 
One notable criticism of the scale is outlined by Ghahari et al. (2014) suggesting the 
MSSM-R may lack additional self-management items relevant for MS; however, it is 
currently the only measure that especially addresses self-management among those with 
MS. An MS-specific measure was felt to be important for the current study.   
The authors cite good internal consistency (Cronbach’s α = .85) for the overall scale in a 
postal survey of patients reporting all types of MS. Wilski et al. (2015) have subsequently 
reported a higher reliability figure (Cronbach’s α = .90) in their study. Four factors are 
shown to demonstrate reliability coefficients above .70, and one (health maintenance 
behaviours) was found to be .59, below acceptable guidelines (Nunnally, 1978). For this 
reason, Bishop & Frain (2011) recommend the use of the composite scale in research. 
Further psychometric evaluation has shown the MSSM-R demonstrates satisfactory to 
good test-retest reliability, moderate to high criterion validity for the factor structure against 









Data for this study will be collected from adults attending the ARRNC. The ARRNC manager 
will be a primary point of contact and will inform MS clinicians about the study by providing an 
information sheet outlining the purpose of the research. 
 
MS clinicians will inform the researcher of potential participants attending that day who meet 
the study inclusion / exclusion criteria from their clinic list. The principal research or a research 
assistant will be present in the ARRNC 2 days per week to recruit. The researchers will 
approach those potential participants during their attendance at the ARRNC and explain 
verbally the purpose of the study and that participation is entirely voluntary. Potential 
participants will also be given an information sheet and the opportunity to ask any questions 
at this point. This will ordinarily happen in the waiting area before or after appointments. 
Alternatively, MS clinicians will introduce the study and provide an information sheet to 
potential participants during appointments. 
  
If initially interested, participant contact details will be requested for the researchers to make 
contact with the potential participant no less than 24 hours and within 1 week of being 
introduced to the study. Potential participants will be invited to take home a research pack 
containing: the participant information sheet, a consent form, the questionnaires and a return 
stamped envelope. To ensure responses remain anonymous, measures will have a unique 
identifier. At this point, potential participants will be informed that taking a research pack home 
does not imply consent and they may choose not to participate even if they accept a research 
pack. 
 
If the individual agrees to take part, they will be invited to complete the questionnaires at home 
and return to the ARRNC via post. Some participants may prefer to complete the 
questionnaires in the waiting area and return the research pack in person. If the individual 
does not wish to participate, they will be thanked for their consideration and their details 
removed from the study list to ensure they are not contacted again regarding the same study  
 
Duration of participant involvement 
 
The recruitment phase of the study is expected to last for approximately 10 months; anticipated 
to start in December 2016. Early termination of the recruitment period will be considered if the 
desired sample size of 120 participants is achieved. The last contact by the principal 
researcher is expected to be in June 2018 to provide a summary of the findings to participants 
following completion of the thesis. Therefore, the maximum time a participant will be involved 
in the study will be 19 months (if recruitment occurs in the first month) and the minimum time 
involved in the study will be 9 months (if recruitment occurs in the final month).
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4. STUDY POPULATION 
 
Number of participants 
 
The current study aims to recruit, on average, 12 MS patients per month to obtain a desired 
sample size of 120 participants. The recruitment period allocated for this study will be 10 





• Participants will be aged 18 years or over. 
• Participants will have a diagnosis of either relapsing-remitting or progressive types of 




• Individuals who have not experienced an MS-related disability or impairment for 12 
months or more. 
• Individuals with significantly impaired intellectual or cognitive functioning (e.g. 
diagnosis of a moderate-severe learning disability or dementia) or severe mental 
health problems that may impede their ability to provide informed consent, understand 
or complete questionnaires. 
• Individuals, who are unable to provide informed consent, understand or complete 
questionnaires due to poor proficiency in the English language. The questionnaires 
used in this study have been standardised in the English language and translating 
these documents will affect the psychometric properties of the questionnaires. This 




Potential participants will always be initially identified by MS clinicians (Neurologists and 
Specialist MS Nurses) conducting outpatient clinics in the ARRNC. If individuals meet inclusion 
criteria for the study, they will be approach in person and provided with a verbal explanation 
of the purpose of the study and an information sheet upon contact with the principal 
researcher, research assistant or MS clinician. Contact details will be requested from potential 
participants and permission sought to contact them by telephone within 1 week and always 24 
hours following introduction to the study. They will then be invited to complete a consent form 




Once appropriate candidates for the study have been identified by MS clinicians, they will be 
approached by the principal researcher, research assistant or MS clinician about the study 
while they are in the ARRNC. A verbal explanation of the study will be provided and potential 
participants will be invited to read over the participant information sheet. They will also have 
the opportunity to ask any questions they might have regarding the study. A request will be 
made for the contact details of potential participants’ and permission to contact them with 1 
week and always 24 hours after being given this information. This is for the purposes of finding 
out whether they would like to take part or not following the “cooling off” period. This will allow 
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potential participants to consider their thoughts and questions before making a decision about 
participation. Upon making contact, the researcher will invite any additional questions about 
the study from potential participants prior to seeking their consent. All potential participants 
will be told they have the right to refuse or withdraw consent to take part in the study at any 
time. Participants who give consent will be asked to return their signed consent form with the 
completed questionnaires via post or in person to the ARRNC. A consent form will be provided 
in the research pack taken home by potential participants to allow them to consider the full 
parameters of what they are consenting to. 
 
Page 135 of 147 
 
5. STATISTICS AND DATA ANALYSIS 
 
Sample size calculation 
 
Regression, moderation and correlational analyses will be used in this study. The statistical 
software G*Power 3 (Faul et al., 2009; available from: http://www.psycho.uni-
duesseldorf.de/abteilungen/aap/gpower3) was used to obtain an a priori sample size for the 
analysis requiring the highest number of participants in the current study. The sample size 
calculated for the multiple hierarchical regression analysis thereby provides sufficient power 
to run the other proposed analyses in this study. 
 
The calculation is based on conventional guidance assuming a medium effect size (Cohen, 
1988), a power level of .80 and an alpha level of .05 (Sink & Stroh, 2006).  The result indicated 
a minimum sample size of 85 is required to run the proposed multiple hierarchical regression 
analyses; with four predictor variables entered first (age, gender, level of education and MS 
symptom severity), followed by another three predictors (depression, patient-clinician 
relationship and value-based living) hypothesised to be important within the current study. 
However, a paper by Green (1991) presents sample size calculations by Cohen (1988), based 
on the same assumptions above, which indicates a sample of 108 would be desirable for a 
multiple regression with seven predictor variables to achieve a medium effect size. However, 
to have sufficient power to detect a more clinically meaningful effect size, this study will seek 
to recruit 120 participants to ensure, as far as possible, that the aims of the project can be 
sufficiently addressed. 
 
Discussions with clinicians at the ARRNC suggest that those affected by MS are a motivated 
participant group, with an estimated 40 per cent response rate to postal surveys. Higher postal 
response rates have been cited in UK studies by the MS Society (available at: 
https://www.mssociety.org.uk/ms-resources/lottery-treatment-and-care-technical-report) and 
by Manouchehrinia et al. (2015) with response rates of 44% and 54%, respectively. Further, 
Nakash et al. (2006) report that postal responses can be improved in health populations by 
offering telephone reminders.  
 
Clinicians at the ARRNC have provided the following information which suggests obtaining a 
sample size of 120 over a 10-month recruitment period is a viable aim: 
 
• Approximately 2000 patients, receiving ongoing input, are held on the MS service 
database in Lothian. 
• Between 15-18 patients attend clinics per day, with clinics operating 5 days per week. 
An estimated 300-360 patients are seen per month. 
• The majority of patients attend appointments at the MS clinic once or twice per year. 
• It is estimated that approximately 70% (250 patients) attending per month will meet 
the inclusion criteria for the current study.  
• Three clinicians (2 specialist MS nurses and a Neurologist) in Lothian have reported 
confidence in obtaining a sample size of 120 participants in the proposed recruitment 
period with the data collection method outlined. 
 
Although recruitment difficulties are not anticipated in NHS Lothian, ethical approval would be 
sought to recruit from another NHS site at a later point in the event that difficulties arise (e.g. 
attrition rates being unexpectedly high). A pre-emptive step has been taken by approaching 
NHS Greater Glasgow and Clyde and NHS Fife to ask if they would be willing to assist with 
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recruitment in the event of under-recruiting in Lothian. The initial IRAS application seeks to 




Primary research questions: 
 
1. Are depression, value-based living and clinician empathy significantly predictive of 
Patient Activation levels over and above patient demographic variables and MS 
symptom severity? 
 
To address primary research question 1, hierarchical multiple regression analysis will be used. 
Data screening, prior to analysis, will examine whether the assumptions of the regression are 
met. These include: missing data; normality, linearity and homoscedasticity of residuals; 
curvilinearity; heterogeneous variance; and influence of outliers (Tabachnick & Fidell, 2014). 
To examine the variance explained by depression, value-based living and the patient-clinician 
relationship, over and above patient demographic factors and MS symptom severity, the 
measure of self-reported Patient Activation will be fixed as the dependent variable. Age, 
gender, level of education and MS symptom severity will be entered in the initial step. 
Depression, value-based living and the patient-clinician relationship will then be entered in the 
second step to examine changes in the variance in Patient Activation. 
 
2. Is Patient Activation linked to MS-specific self-management behaviours? 
 
Primary research question number 2 will be explored through a correlation analysis examining 
the association between Patient Activation and self-management behaviours associated with 
MS. Previous data screening, will examine whether the required assumptions of the regression 
are met. 
 
3. Are value-based living and clinician empathy significantly predictive of depression 
or anxiety over and above patient demographic variables and MS symptom severity? 
 
Primary research question number 3 will be addressed using two separate hierarchical 
multiple regression analyses. Previous data screening, will examine whether the required 
assumptions of the regression are met. Predictive values of value-based living and clinician 
empathy over and above patient demographic factors and MS symptom severity, will be 
examined by fixing depression as a dependent outcome variable in one analysis and anxiety 
as a dependent outcome variable in a second analysis. Age, gender, level of education and 
MS symptom severity will be entered in the initial step in both analyses. Value-based living 
and the patient-clinician relationship will then be entered in the second step of both analyses 
to examine changes in the variance in both depression and anxiety. 
 
4. Does value-based living moderate the relationship between symptom severity and 
depression? 
 
Primary research question number 4 will be addressed using moderation analysis. For testing 
moderation, several papers recommend moderated regression analysis to examine interaction 
effects (Cohen & Cohen, 1983). Value-based living will be examined as a moderator of 
depression and MS symptom severity. Depression and value-based living will be entered in 
the first step of the regression analysis. In the second step, the interaction terms between 
depression and value-based living will be entered. A significant increase in the variance of 
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patient-reported MS symptom severity following the second step of the regression analysis will 
indicate a moderating effect of value-based living (Cohen & Cohen, 1983; Kleinbaum et al., 
1988). 
 
Secondary research question: 
 
What levels of Patient Activation are present in an outpatient group of MS patients in 
the UK?  
 
To address the secondary research question, descriptive statistics will be used to demonstrate 




6. REPORTING PUBLICATION AND NOTIFICATION OF RESULTS 
 
The results of the study will be written up in a thesis format and submitted to the Doctorate of 
Clinical Psychology at the University of Edinburgh. The format of the thesis will include both a 
systematic review and a journal article. It is the intention of the principal researcher to submit 
both for publication to a journal relevant to clinical and health psychology. The results of the 
study will also be presented within NHS Lothian MS services. Where participants have 
indicated they wish to receive a written summary of the findings from the study, these will be 
sent to individuals via post. A summary of the findings and the final journal article will also be 
made available to the MS Society for dissemination of the findings to the wider population of 
those affected by MS. 
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APPENDIX 1: GLOSSARY OF TERMS FOR REFERENCE 
 
ACCEPTANCE and COMMITMENT THERAPY – A psychological intervention that 
uses acceptance and mindfulness strategies and a commitment to changing behaviour to help 
a person adapt to and cope with changing circumstances or demands in their life. 
 
ANNE ROWLING REGENERATIVE NEUROLOGY CLINIC – A charitable research facility of 
the University of Edinburgh which specialises in neurological conditions like Multiple Sclerosis. 
 
CLINICIAN EMPATHY - The extent to which a patient feels listened to and understood by their 
healthcare professional during the clinical consultation process.  
 
DEMOGRAPHIC VARIABLES – Characteristics of a population of people such as age, gender 
and level of education.  
 
DEPRESSION - A group of symptoms that include: low mood or negative emotion that lasts 
for a period of two weeks or longer which is present in most situations; feelings of 
worthlessness; loss of enjoyment in previously enjoyed activities; low energy and motivation; 
sleep and appetite disturbances (including over/under eating or sleeping); poor concentration 
and memory; and lowered sex drive. This list is not exhaustive of the symptoms experienced.  
 
INTERNATIONAL CLASSIFICATION OF DISEASES -10 (ICD-10) – A list of medical 
classifications of physical and mental disease and codes published by the World Health 
Organisation which includes symptoms and treatments. 
 
LONG TERM CONDITIONS - A condition that cannot be cured with current medical 
knowledge but can be managed with medication and other therapies. Examples of Long Term 
Conditions are diabetes, heart disease and MS. 
 
MULTIPLE SCLEROSIS (MS) - A chronic disease which gets worse over time. It involves 
damage to the sheaths of nerve cells in the brain and spinal cord. Symptoms can include 
numbness, severe fatigue, pain, mobility problems and impairment of speech and of muscular 
coordination. This list is not exhaustive of symptoms experienced. 
 
MS TYPE – Those affected by MS can be diagnosed with “relapsing-remitting” or “progressive” 
types of MS. With relapsing remitting MS, people have “attacks” of symptoms which then fade 
away either partially or completely. Around 85 per cent of people with MS are diagnosed with 
this relapsing-remitting MS. Secondary progressive MS comes after a diagnosis of relapsing-
remitting MS and is thought to be a result of a build-up of damage to nerve cells by “attacks.” 
Primary progressive MS is rarer and affects about 10 to 15 per cent of people diagnosed with 
MS. Symptoms gradually get worse over time, rather than appearing as “sudden attacks.” 
 
PATIENT ACTIVATION - The willingness and capacity of a person to take on the responsibility 
of self-managing their own health. It is measured by the Patient Activation Measure (PAM-13) 
which asks about a person’s knowledge, beliefs, confidence and self-efficacy in relation to 
managing a health condition. Resulting scores on the PAM-13 places people on one of four 
levels of activation. Levels range from: Level 1: Disengaged and overwhelmed; Level 2: 
Becoming aware, but still struggling; Level 3: Taking action; Level 4: Maintaining behaviours 
and pushing further.  
 
QUALITY OF LIFE - The standard of health, comfort, and happiness experienced by an 
individual or group. 
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SYMPTOM SEVERITY - How severe a physical symptom feels in terms of intensity, sensation 
or duration.  
 
VALUE-BASED LIVING - The extent to which a person is engaged with living in line with their 
personally held values. Values differ from person to person, as do the levels of importance 
people place on their values. Self-assessment of value-based living is completely subjective.  
 
VARIANCE - The variation of a characteristic in a population (e.g. levels of height will vary 
within a population). 
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Appendix G:  Study Information Sheet 
 
 
      
 
 
Participant Information Sheet and Consent Form 
Patient Self-Management in Multiple Sclerosis: the role of depression, 
value-based living and perceived clinician empathy. 
 
You are being invited to take part in a research study.  Before you decide whether or 
not to take part, it is important for you to understand why the research is being done 
and what it will involve.  Please take time to read the following information carefully. 
Talk to others about the study if you wish.  Contact us if there is anything that is not 
clear or if you would like more information.  Take time to decide whether or not you 
wish to take part. 
 
What is the purpose of the study? 
The purpose of the study is to investigate patient self-management in people with Multiple 
Sclerosis, also known as ‘Patient Activation’, and the factors which may influence this.  ‘Patient 
Activation’ reflects the willingness of a person to self-manage their health condition, as well as 
their ability to do so. This is important for effective self-management and better health.  
Studying patient self-management is important to better identify the needs of people with MS 
in relation to self-managing their illness and to understand what additional support is needed. 
This study hopes to recruit 120 people to fulfil the purpose of this research. 
 
Why have I been asked to take part? 
You have been asked to take part as you have been previously diagnosed with Multiple 
Sclerosis (MS) and attend the Anne Rowling Regenerative Neurology Clinic to see an MS 
clinician. 
 
Do I have to take part? 
No, it is up to you to decide whether or not to take part.  If you do decide to take part, you will 
be given this information sheet to keep and be asked to sign a consent form.  If you decide to 
take part, you are still free to withdraw at any time and without giving a reason.  Deciding not 
to take part or withdrawing from the study will not affect the healthcare that you receive, or 
your legal rights. 
 
What will happen if I take part? 
Your involvement in the study will take around 30 minutes in total. You will be asked for some 
demographic information and provided with six questionnaires to complete asking about: 
‘Patient Activation’; self-management activities related to MS; MS symptoms; mood; the 
relationship you have with your MS clinician; and value-based living. 
 
If you think you might like to take part, you will have the opportunity to ask further questions. 
We will provide you with a research pack containing a consent form and the questionnaires. 
You will be given additional time to think about taking part and we will ask for your contact 
details and permission to contact you within 1 week and always at least 24 hours after being 
given this information. This is to find out your decision and remind you to return the consent 
form and questionnaires if you still wish to take part. You have the right to change your mind 
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about participating in the study or withdraw at any time. If you decide you no longer wish to 
take part or you decide to withdraw from the study, this will not affect you or the care you 
receive at the clinic in any way.  
 
What are the possible benefits of taking part? 
You may not directly benefit from taking part in this study, although the findings may be useful 
or interesting to you. It is hoped that the results from this study will inform on the future 
healthcare of other patients. It is hoped that in the longer term, MS services developing patient-
centred approaches to the care and management of patients will benefit from the results of 
this research.  
 
What are the possible disadvantages and risks of taking part? 
It is not thought that there are many disadvantages, however, we recognise there might be a 
burden of time (30 minutes on average). In addition, completing the questionnaire asking about 
your mood may highlight some concerns for individuals around their own mood and wellbeing. 
If you feel concerned about your mood or you think you might need some support, please 
speak to your GP or an MS clinician to discuss this further.  
 
Will my taking part in the study be kept confidential? 
Information will be collected by questionnaires. All information which is collected about you 
during the course of the research will be kept strictly confidential and any information about 
you which leaves the clinic will have your name, address and other identifiable information 
removed so that you cannot be recognised.  The researchers may need access to some of 
the data in your medical records to carry out this research. 
 
To ensure that the study is being run correctly, we will ask your consent for responsible 
representatives from the Sponsor (University of Edinburgh) and NHS Lothian to access your 
medical records and data collected during the study, where it is relevant to you taking part in 
this research. The Sponsor is responsible for overall management of the study and providing 
insurance and indemnity. With your consent we will inform your GP that you are taking part. 
 
Will my information be shared? 
For the purposes of making improvements to their questionnaires, some organisations ask 
that data from their questionnaires is sent back to them. Before the data is sent back it is made 
completely unidentifiable.  
 
Unidentifiable questionnaire responses will be shared with Insignia Health LLC who hold the 
exclusive rights to the Patient Activation Measure (PAM), one of the questionnaires you would 
be asked to complete. Participant’s identity and personal information will not be shared with 
Insignia Health LLC. 
 
Insignia Health will not alter your data, share it with other parties, or publish results. They will 
only use unidentifiable data to continually improve the Patient Activation Measure (PAM) and 
its guidelines for use. 
 
What happens when the study is finished? 
At the end of the study we will analyse the data collected and the results will be written up as 
a research report. Personal data collected during the study will be disposed of securely within 
12 months after the study has ended.   
 
Unidentifiable research data (data from which no individuals could be identified) will be 
archived and stored at the University of Edinburgh, where it will be used to assist publication 
of results from the project and to facilitate relevant secondary uses which the project team 
deem would enable additional public benefit.  
 
What will happen to the results of the study? 
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The study will be written up in the format of a thesis and submitted to the University of 
Edinburgh for scientific review. It is intended that a paper will be submitted for publication to a 
scientific journal in the field of clinical and health psychology. You will not be identifiable in any 
published results. A summary of the findings from the study will be made available to 
participants who indicate they would like to receive this. This summary would be sent to 
participants by post. 
 
Who is organising the research and why? 
This study is being done in fulfilment of the requirements of the Clinical Psychology Doctoral 
Training Programme at the University of Edinburgh. It is an academic, non-profit piece of work 
but may receive some financial support from the University of Edinburgh and NHS Lothian. 
 
Who has reviewed the study? 
The study proposal has been reviewed by NHS South West Exeter Research Ethics 
Committee. All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee. A favourable ethical opinion has been obtained from NHS South 
West Exeter REC.  NHS management approval has also been obtained. 
 
Can I speak to someone after I have taken part? 
You may wish to ask further questions about the study or reflect on your experience of 
answering the questionnaires after taking part. If you would like to discuss anything after 
participating, you can contact the researcher on the telephone number provided below. The 
researcher will ask you what you would like to discuss and focus on addressing your 
questions, thoughts or issues raised in relation to the study. 
 
If the researcher has any further concerns about you following the discussion, they would 
share this information with your direct clinical care team within the MS service. They may 
also contact your GP if necessary; however, we would always try to speak to you about this 
first.   
 
If you would like to discuss anything about the study before or after taking part, please 
contact: 
Laura Alexander, Trainee Clinical Psychologist / NHS Lothian 
School of Health in Social Science,  
Doorway 6, Medical Quad, Teviot Place 
Edinburgh 
EH8 9AG 
Tel: 07979 375799  Email: s1578313@sms.ed.ac.uk 
 
If you would like to discuss this study with someone independent of the study please 
contact: 
Azucena Guzman, Lecturer in Health and Ageing, University of Edinburgh 
Room 2.10, Doorway 6, Medical Quad, Teviot Place 
Edinburgh 
EH8 9AG 
Tel: 0131 651 5162  Email: Azucena.Guzman@ed.ac.uk 
 
If you wish to make a complaint about the study please contact NHS Lothian: 
NHS Lothian Complaints Team 
2nd Floor, Waverley Gate, 2 - 4 Waterloo Place 
Edinburgh 
EH1 3EG 
Tel: 0131 536 3370  Email: feedback@nhslothian.scot.nhs.uk. 
 
Thank you for taking the time to read this information sheet.
   
Page 147 of 147 
 
Appendix H: Study Consent Form 
 
 
           
 
CONSENT FORM 
Patient Self-Management Study 
 
Participant ID:  
 
 
Laura Alexander, Trainee Clinical Psychologist / NHS Lothian 
School of Health in Social Science, Doorway 6, Medical Quad, Teviot Place 
Edinburgh, EH8 9AG 
Tel: 07979 375799  Email: s1578313@sms.ed.ac.uk 
  
Please initial box 
 
1. I confirm that I have read and understand the information sheet (version no. 3, date 
20/12/2016) for the above study and have had the opportunity to consider the information 
and ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at any time, 
without giving any reason, without my medical care or legal rights being affected. 
 
3. I understand that relevant sections of my medical notes and data collected during the 
study may be looked at by individuals from the regulatory authorities and from the 
Sponsor(s) (NHS Lothian and the University of Edinburgh) or from the/other NHS Board(s) 
where it is relevant to my taking part in this research. I give permission for those individuals 
to have access to my records. 
 
4. I agree to my unidentifiable data being shared with Insignia Health LLC for the purposes 
of ongoing improvements to the Patient Activation Measure. 
 
5. I agree to my General Practitioner being informed of my participation in this study and 
being contacted should concerns about my wellbeing arise. 
 
6. I would like to receive a summary copy of the study results by post.   
 
7. I agree to take part in the above study. 
 
________________________ ________________ ________________ 
Name of Participant  Date Signature 
 
________________________ ________________ ________________ 
Name of Person taking consent Date  Signature 
